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Abstract
Coenzyme A (CoA) and CoA thioesters are central to numerous metabolic pathways. However, the inability
to synthesize isotopically labeled CoA has limited analytical methods to measure these compounds. In this
thesis, we developed Stable Isotope Labeling with Essential nutrients in Cell culture (SILEC), a method to
generate isotopically labeled CoA derivatives by growing cells in a labeled CoA precursor, [13C15N]-
pantothenate. Labeled CoA derivatives were used as internal standards in a stable isotope dilution liquid
chromatography-mass spectrometry (LC-MS) method to measure changes in short chain acyl-CoA species.
This assay was also adapted to include measurement of glutathione-CoA (CoASSG), a mixed disulfide
increased in mitochondrial oxidative stress. Menadione significantly increased intracellular levels of CoASSG,
and decreased levels of CoASH through the formation of CoA-menadione adduct. In addition, rotenone, an
organic pesticide and potent complex I inhibitor, induced a dose-dependent decrease in succinyl-CoA and
increase in beta-hydroxybutyryl-CoA (BHB-CoA) in multiple human cell lines, as well as inhibited glucose-
derived acetyl-CoA and succinyl-CoA biosynthesis. This SILEC assay was further adapted for use in freshly
isolated human platelets to assess metabolic changes in Friedreich's Ataxia (FA), an inherited mitochondrial
disease caused by mutations in the frataxin gene. FA patients were found to have significantly decreased
acetyl-CoA: succinyl-CoA ratio, consistent with an in vitro siRNA knockdown model of frataxin. Finally,
platelets were demonstrated to serve as a powerful ex vivo metabolic and toxicologic challenge platform
evidenced by treatment with propionate, rotenone and a number of stable isotope metabolic tracers. Together,
these methods provide a paradigm for the discovery of novel biomarkers for metabolic and mitochondrial
disease.
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Abstract 
 
SILEC: A NEW TOOL TO STUDY 
MITOCHONDRIAL AND METABOLIC DISEASE 
 
Sankha S. Basu 
Ian A. Blair, PhD 
 
 Coenzyme A (CoA) and CoA thioesters are central to numerous metabolic 
pathways.  However, the inability to synthesize isotopically labeled CoA has limited 
analytical methods to measure these compounds.  In this thesis, we developed Stable 
Isotope Labeling with Essential nutrients in Cell culture (SILEC), a method to generate 
isotopically labeled CoA derivatives by growing cells in a labeled CoA precursor, 
[13C3
15N]-pantothenate.  Labeled CoA derivatives were used as internal standards in a 
stable isotope dilution liquid chromatography-mass spectrometry (LC-MS) method to 
measure changes in short chain acyl-CoA species.  This assay was also adapted to include 
measurement of glutathione-CoA (CoASSG), a mixed disulfide increased in 
mitochondrial oxidative stress.  Menadione significantly increased intracellular levels of 
CoASSG, and decreased levels of CoASH through the formation of CoA-menadione 
adduct.  In addition, rotenone, an organic pesticide and potent complex I inhibitor, 
induced a dose-dependent decrease in succinyl-CoA and increase in β-hydroxybutyryl-
CoA (BHB-CoA) in multiple human cell lines, as well as inhibited glucose-derived 
acetyl-CoA and succinyl-CoA biosynthesis.  This SILEC assay was further adapted for 
vi 
 
use in freshly isolated human platelets to assess metabolic changes in Friedreich’s Ataxia 
(FA), an inherited mitochondrial disease caused by mutations in the frataxin gene. FA 
patients were found to have significantly decreased acetyl-CoA: succinyl-CoA ratio, 
consistent with in vitro siRNA knockdown model of frataxin.  Finally, platelets were 
demonstrated to serve as a powerful ex vivo metabolic and toxicologic challenge platform 
evidenced by treatment with propionate, rotenone and a number of stable isotope 
metabolic tracers.  Together, these methods provide a paradigm for the discovery of 
novel biomarkers for metabolic and mitochondrial disease. 
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Chapter 1: The metabolic role of CoA and developments in the analytical 
measurement of CoA derivatives 
 Despite the discovery of mitochondria more than one hundred years ago, 
biological advances over the past half-century have been largely defined by the discovery 
of DNA, the foundation of genetic theory, and the elucidation of the human genome. 1, 2  
The parallel development of mitochondrial biology has been largely overshadowed until 
recently, as both scientists and clinicians have begun to appreciate the wider role 
mitochondria play not only in metabolism, but also in the pathogenesis of a wide variety 
of human diseases.3-5  The ability to rigorously and quantitatively measure changes in 
mitochondrial metabolites is critical in understanding mitochondrial pathology and 
finding biomarkers for many of these diseases.6  A brief introduction is provided for the 
reader to better appreciate the research presented in this thesis.   
 
1.1 Mitochondria and metabolic disease 
Mitochondria are specialized eukaryotic organelles that provide many of the 
bioenergetic requirements of the cell.7  Unlike most organelles, mitochondria contain an 
inner and outer membrane.  Enclosed within the inner membrane is the mitochondrial 
matrix, the location of various metabolic processes such as the Krebs cycle, fatty acid 
oxidation (FAO), and oxidative phosphorylation (OXPHOS) (Figure 1.1).  Eukaryotic 
cells contain hundreds to thousands of mitochondria with a wide range of OXPHOS 
capacity, depending on the energy requirements of the tissue.8, 9   Also, unlike other 
organelles, mitochondria contain their own DNA (mtDNA), which is distinct from 
nuclear DNA (nDNA).10   This peculiarity of mitochondria is explained by the generally  
1 
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Figure 1.1 Electron transport chain and oxidative phosphorylation. OXPHOS is 
accomplished by a set of five enzymatic complexes (I-V).  Complex I is normally the 
point of entry for the majority of electrons in the respiratory chain that eventually cause 
sequential 1-electron reductions of molecular oxygen to water. In addition, complex I 
translocates protons generated by the Krebs cycle from the mitochondrial matrix to the 
intermembrane space. This establishes the electrochemical gradient required for ATP 
biosynthesis.  Complex I (NADH dehydrogenase) and complex II (succinate 
dehydrogenase) use NADH and FADH2, respectively, to reduce ubiquinone.  This 
subsequently reduces cytochrome C (complex III) and complex IV, ultimately reducing 
molecular oxygen to form water.  Cumulatively, complexes I-IV generate a proton 
gradient in the mitochondrial intermembrane space, which reenter the matrix through 
ATP synthase (Complex V) to form ATP from ADP.  In this way, chemical energy from 
carbon sources is converted into ATP, the universal energy currency used in the cell.   
3 
 
accepted endosymbiotic theory of mitochondrial origin, which proposes that 
mitochondria were originally OXPHOS-capable eubacteria that formed a symbiotic 
relationship with another microorganism providing increased energy efficiency in 
exchange for structural and nutritional advantages.7  It is believed that these eubacteria 
eventually evolved to become the modern-day eukaryotic mitochondria.  Plant 
chloroplasts, which also contain their own DNA, are believed to have arisen through a 
similar mechanism.11 It has been suggested that this mitochondrial evolutionary origin 
itself may be a factor in the pathogenesis of various diseases.12 
A number of genetic diseases have been linked to mutations in mtDNA.4   
Although mtDNA contains only 13 genes,13 compared to the greater than 30,000 genes in 
nDNA, mutations in these genes can lead to debilitating tissue-specific diseases, most 
notably several optic neuropathies.14   Curiously, all mitochondria are inherited from the 
egg rather than the sperm so mitochondrial diseases have a unique maternal inheritance 
pattern.15 Due to the central role of mitochondria in metabolism and bioenergetics, it is 
not surprising that mitochondrial dysfunction often leads to pathologic features in tis ues 
with higher metabolic energy demands.16 In addition to diseases with mitochondrial 
inheritance, mitochondrial dysfunction has been implicated in diabetes,17 h art disease,18 
cancer,19 Alzheimer’s disease (AD),20 Parkinson’s disease (PD),21 autism,22 and 
numerous other neurological and metabolic diseases.23, 24 In addition, many 
environmental toxins, pesticides in particular, are thought to exhibit their toxicity through 
inhibition of mitochondrial function.25, 26  As a result, environmental insults, particularly 
in the context of genetic predispositions may be the etiological factor of many diseases of 
idiopathic origin.   There is also mounting evidence clinical manifestations such a 
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idiosyncratic adverse drug reactions may also involve metabolic and mitochondrial 
toxicity.27  Central to many of these processes is the molecule coenzyme A (CoA). 
 
1.2 Coenzyme A (CoA) 
 CoA is a ubiquitous intracellular thiol and coenzyme common to all forms of 
life,28 serving both metabolic and detoxification functions, ranging from fatty acid 
metabolism to xenobiotic acetylation.29  In fact, it is estimated that CoA is used by 4% of 
all cellular enzymes.30  CoA is composed of three components: an ATP moiety, a 
cysteinyl group, and a pantethine group, which originates from pantothenate (vit min B5).  
In addition to CoA, pantothenate is utilized in the synthesis of the prosthetic group in 
acyl-carrier protein (ACP).31  Plants, fungi and many prokaryotes are capable of 
synthesizing pantothenate from its constituent amino acids, valine and aspartate (Figur  
1.2).32, 33  Animals, however, are not capable of de novo pantothenate synthesis and as a 
result, require it in their diet.34  From pantothenate, CoA is synthesized through five 
enzymatic steps.35  The first enzyme, pantothenate kinase, which converts pantothenate to 
pantethine-phosphate, is the rate-determining step of CoA biosynthesis.36  Pantothenate 
deficiency is rare in humans, but can manifest clinically in neurological, gastrointestinal 
and metabolic symptoms, all of which can be reversed by pantothenate 
supplementation.37    
CoA primarily functions as an acyl carrier molecule, through a thioester linkage 
between the acyl group and the free thiol of CoASH (reduced CoA).  There are numerous 
CoA-derivatives, including a thioester for most individual fatty acids (a comprehensive 
list is provided in the appendix, Table A.1).  One important class of acyl-CoA species is  
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Figure 1.2 Pantothenate and CoA biosynthesis. As illustrated here, plants, fungi and 
many prokaryotes are capable of de novo pantothenate synthesis from valine and 
aspartate, while other organisms require it as an essential nutrient.  Pantothenate is 
subsequently converted to CoA through the sequential action of five enzymes.  CoA can 
then be incorporated into various acyl-CoA thioesters.  Previously published in Basu, 
Blair. Nat Protocols, 2011. 
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the short chain acyl-CoA thioester class, the measurement of which is the focus of this 
thesis.  Figure 1.3 illustrates the role of some of these compounds in relation to the Krebs 
cycle.  Of all short chain acyl-CoA species, acetyl-CoA is most prominent due its diverse 
functions.  Pyruvate formed by glycolysis is converted irreversibly by pyruvate 
dehydrogenase into acetyl-CoA, which condenses with oxaloacetate to form citrate, 
serving as a carbon entry point in the Krebs cycle.  Each turn of the cycle produces 
reducing equivalents in the form of NADH and FADH2, which are used in OXPHOS to 
produce ATP (Figure 1.1).  Another important CoA thioester is succinyl-CoA, a Krebs
cycle intermediate formed from α-ketoglutarate (aKG) by the action of aKG 
dehydrogenase.  Succinyl-CoA is then converted by succinyl-CoA synthetase into 
succinate, which along with FADH2 is utilized by succinate dehydrogenase (complex II) 
to reduce ubiquinone and generate fumarate (Figure 1.1). As compared to glycolysis, in 
which a single glucose molecule can produce a net of 2 ATP, the coupled action of the 
Krebs cycle and OXPHOS produces 36-38 ATP from a single molecule of glucose, 
thereby providing a tremendous increase in energy efficiency.  This improvement is 
particularly striking in the case of β-oxidation of fatty acids (FAO).  In FAO, fatty acids 
which are often transported or stored as triglycerides are broken down through a 
sequential process.  In each cycle, the fatty acyl-CoA is shortened by two carbons, which 
are released as acetyl-CoA and a new acyl-CoA thioester, two carbons shorter than the 
original, is formed.  The carbons from acetyl-CoA can then enter the Krebs cycle as 
previously described, while the shortened acyl-CoA can undergo another round of 
oxidation.  The penultimate CoA thioester formed from even chained fatty acids is BHB-
CoA.  The complete oxidation of a single palmitate molecule can provide 108 ATP.  On  
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Figure 1.3 Short chain acyl-CoA thioesters and the Krebs cycle.  The structure of CoA 
and various important CoA thioesters (blue) and their relative position in relation to the 
Krebs cycle are illustrated.    
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the other hand, acetyl-CoA can be converted to malonyl-CoA as the first step in fatty acyl 
synthesis.  In the case of odd chain fatty acids, the last acyl-CoA thioester is propionyl-
CoA, which contains three carbons.  This can subsequently enter the Krebs cycle through
succinyl-CoA.  3-hydroxymethyl-3-glutyryl-CoA (HMG-CoA) is another criti ally 
important short chain acyl-CoA thioester involved in several metabolic pathways 
including ketogenesis and cholesterol synthesis.  In fact, HMG-CoA synthase is the rate 
limiting enzyme of ketogenesis,38 a metabolic state in which ketone bodies are produced 
by the liver to serve as alternative energy sources to glucose for the brain, and is induced 
by starvation or high protein and low carbohydrate diets.  HMG-CoA reductase is the rate 
limiting enzyme in cholesterol synthesis and is the target of the widely prescrib d statin 
class of drugs (HMG-CoA reductase inhibitors).39  Although these are only a few of the 
many CoA thioesters, we have primarily focused on these particular species due to their 
critical importance in metabolism. 
In addition to functioning as a fatty acyl-carrier, CoA is used in several other 
capacities as well, including playing a prominent role in detoxification.  One such role is 
serving as a cofactor in phase II acetylation, where the acetate from acetyl-CoA is 
activated and transferred to the metabolite.  In fact, it was the acetylation properties of 
CoA that led to its initial discovery by Fritz Lipmann in 1945,40 (the “A” in CoA was 
used to represent “activation of acetate”).41 Also, like glutathione (GSH), CoASH can 
react with xenobiotic compounds and electrophiles.42, 43  It has also been shown that 
CoASH is the major reducing intracellular thiol in Staphylococcus Aureus, likely due to 
the fact that these bacteria do not contain GSH.44  For this reason, along with the 
structural elucidation of the enzymes in CoA synthesis,34 there has been a renewed 
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interest in this biosynthetic pathway for potential antimicrobial drug targets.33  
Interestingly, the mixed disulfide glutathione-CoA (CoASSG) has also been shown to 
form in vivo,45-48 though its exact role and mechanism of formation remains unclear.49-52  
However, it has been shown that the ratio of CoASSG: CoASH is increased in settings of 
mitochondrial oxidative stress such as hyperoxia53, 54 and seizures,55 indicating that like 
GSSG:GSH ratio, which is used as a marker of cellular oxidative stress, CoASSG: 
CoASH ratio may serve as an indicator of mitochondrial oxidative stress.  Still, new roles 
for CoA continue to be discovered, as is exemplified by the recent discovery of CoA-
linked RNA adducts56 as well as CoA-electrophile adducts.43  The expansive roles of 
CoA as well as studies showing that levels of CoA species are perturbed in many 
pathological settings including diabetes,57, 58  as well as various inherited metabolic 
disorders,59-64 has revitalized efforts to develop methods to measure these species. 
 
1.3 Measuring CoA 
Given that CoA-activated compounds can differ so dramatically in their chemical 
properties, the class of CoA species to be measured must be considered first.  These can 
be broken down as follows: reduced CoA (CoASH), acyl-CoA thioesters, CoA-disulfides, 
and other CoA-activated compounds, which may include a broad number of CoA adducts 
bound to exogenous or endogenous electrophiles.  Although there is a continuum in the 
length of the carbon tails of acyl-CoA thioesters, these can be basically broken d wn into 
short- (up to 5 carbons), medium- (up to 10 carbons), long- (up to 20 carbons) and very 
long-chain (more than 20 carbons) acyl-CoA species.  Due to differences in chemical and 
physical properties of these different acyl-CoA species, different classes of CoA 
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derivatives require different extraction methods.  In general, short chain acyl-CoA 
species are acid soluble and if a biological sample is sonicated or homogenized in a 
strong acid solution, the acid soluble short chain acyl-CoA species can be extracted.65, 66  
This can be accomplished by using sulfosalicylic acid (SSA), perchloric acid or 
trichloroacetic acid (TCA).  In general, a 10% TCA solution was the most optimal for 
short chain acyl-CoA extraction.67 After acid extraction, these short chain acyl-CoA 
species can be further purified using solid phase extraction (SPE) or repeated ether 
extraction to remove the TCA.  SPE extraction was generally favorable for both ease and 
cost factors.67  For medium, long and very long chain acyl-CoA molecules, performing a 
liquid-liquid extraction with an organic solvent is ideal.68-70   
Also, the source of CoA is important as well.  CoA molecules can be measured 
from whole cells (or tissues), or from isolated mitochondria.  While the ability to isolate 
and study viable mitochondria set the foundation for much of our understanding of 
mitochondrial biology,71 the act of isolating mitochondria can generate oxidative stress 
leading to artifactual changes attributed to sample processing.72  More importantly, when 
developing biomarker studies to measure CoA changes, whole tissues or cells (such as 
fibroblasts or blood cells) need to be extracted since CoA species are intracellular.  
Further isolation of mitochondria from these cells would not only introduce oxidative 
stress, but would also be laborious and clinically impractical.  Therefore, wholecell 
assays were the chosen method in our work. 
Like mitochondria, the discovery of CoA also preceded the discovery of the 
double helix.  CoA was first described by Fritz Lipmann in 1945, for which he was 
eventually awarded the Nobel Prize in Medicine in 1953.41  Over the next forty years, a 
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significant amount of research was focused on the identifying, separating and accurately 
measuring acyl-CoA thioesters in biological systems.  The majority of methods 
developed through these decades focused on high performance (HP) liquid 
chromatography (LC) coupled with ultraviolet (UV) detection.65, 66, 73  CoA species 
exhibit a characteristic UV absorption at 254 nm.  Since all CoA thioesters contain the 
CoA moiety, they can be readily detected if properly separated.  However, because UV 
detection is used, complete baseline separation is required for measurement of CoA 
species.  To accomplish this for short-chain acyl-CoA species, high concentrations of 
phosphate buffer were needed to successfully separate a broad number of these species.65  
Additional LC-UV methods were also made for other CoA derivatives.  One problem 
with such methods is lack of specificity due to co-eluting peaks.  More importantly, 
however, even the best methods had a sensitivity which was generally in the high 
picomolar to single-digit nanomolar range.  While this may be adequate from larger 
pieces of animal tissue containing abundant CoA species, this is inadequate for 
practicable in vitro analysis or clinical studies involving much smaller amounts of 
biological material.  Over the next two decades, significant technogical improvements in 
mass spectrometry (MS) have allowed not only increased specificity but also dr matic 
improvements in sensitivity of CoA analysis.  These LC-MS methods have been used i  
the measurements of short chain acyl-CoA species,67, 74-76 as well as medium and long 
chain acyl-CoA species.68-70  Although MS methodology has notable advantages in  
sensitivity and specificity, it also can present variable precision and accuracy, especially 
with electrospray ionization (ESI).77, 78 Stable isotope dilution mass spectrometry can be 
used to overcome this problem. 
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1.4 Stable isotope dilution MS 
LC-selected reaction monitoring (SRM)/MS provides a highly sensitive and 
specific platform to measure a broad range of analytes in a variety of complex biological 
matrices.79 In addition, advancements in high resolution mass MS80, 81 as well as the 
development of more dynamic software platforms82-84 have provided scientists the 
capability of measuring thousands of different analytes in a single run, making MS the 
optimal methodology for robust high-throughput metabolomic and proteomic analyses.85, 
86  Nonetheless, appropriate internal standards are critical for the success of any MS-
based method, particularly when measuring endogenous metabolites in biological 
samples, due to matrix effects on analyte stability, extraction, and ionizat efficiency.77, 
78, 87-90  To account for these effects, an internal standard that faithfully reproduces the 
biological and chemical properties of the analyte of interest is needed.91 Stable isotope 
analogs represent the best internal standards for MS-based analyses because they have the 
same biological and physicochemical properties as the analyte of interest, but can still be 
distinguished by a mass spectrometer.91 
 
1.5 Stable Isotope Labeling with Amino acids in Cell culture (SILAC) 
Difficulty in chemically synthesizing stable isotope analogs of complex biological 
molecules has spurred the development of techniques to generate these standards in 
biological systems.92-94 In the case of proteins, a method called SILAC has been 
developed (Figure 1.4).95 After generation of isotopically labeled cells, one of two 
possible experimental modalities can be used.  In the “classical” SILAC approach, an  
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Figure 1.4 Stable Isotope Labeling with Amino acids in Cell culture (SILAC).  In this 
method, cells are grown in the presence of a stable isotope-labeled essential ami o acid 
such as lysine or leucine, with the unlabeled form specifically omitted.  The inability to 
synthesize these essential amino acids de novo results in their exclusive uptake and 
incorporation into cellular proteins.  After serial passages in this media, greater than 99% 
of these residues are labeled.   These can then be used for stable isotope dilution MS. 
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equal number of labeled and unlabeled cells are subjected to different stimuli, mixed
processed together and analyzed by MS.95  Alternatively, the labeled cells can be lysed to 
produce a stable isotope labeled proteome internal standard (SILAP),96 which can then be 
spiked into different experimental samples to normalize the measured analytes for 
relative quantitation.97-99  The advantage of the latter approach is the ability to apply these 
standards to both in vitro or in vivo samples, as well as avoiding any biological 
perturbations introduced by growing the cells in labeled amino acids. 
Like proteins, CoA and other endogenous metabolites have been difficult to 
chemically synthesize and consequently labeled analogs for many of these compounds 
are not commercially available. In the following chapter, we present a novel methodology 
to generate isotopically labeled CoA internal standards. 
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Chapter 2: The development of Stable Isotope Labeling by Essential Nutrients in 
Cell Culture (SILEC) for preparation of labeled CoA and its thioesters 
 
2.1 Abstract 
While CoA and acyl-CoA thioester derivatives are central players in numerous 
metabolic pathways, the lack of a commercially available isotopically labeled CoA limits 
the development of rigorous stable isotope dilution MS-based methods.  In this chapter, 
we adapted SILAC methodology to biosynthetically generate stable isotope labeled CoA 
and CoA-thioester analogs for use as internal standards in an LC-SRM/MS assay.  This 
was accomplished by incubating murine hepatoma cells (Hepa 1c1c7) in media in wh ch 
pantothenate, a CoA precursor, was replaced with [13C3
15N1]-pantothenate.  Efficient 
incorporation into various CoA species was optimized to > 99% [13C3
15N1]-pantothenate 
labeling after three passages.  Charcoal-dextran stripped FBS (csFBS) was found to be 
optimal for serum supplementation due to its lower contaminating unlabeled pantothenate 
content.  In addition, a method to generate specific CoA derivatives was demonstrated by 
treating SILEC- labeled cells with propionate to generate [13C3
15N1]-propionyl-CoA.  
Labeled cells were harvested, and stable isotope labeled CoA species were extract d and 
utilized as internal standards for CoA thioester analysis in cell culture as well as in mouse 
tissue.  This SILEC methodology can serve as a paradigm for using vitamins and other 
essential nutrients to generate stable isotope standards that cannot be readily synthesized. 
 
 
Portions of this chapter have been previously published (Basu et al. Anal Chem, 2011; Basu SS, Blair IA. 
Nat Protocols, 2011).
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2.2 Introduction 
 
CoA, a ubiquitous fatty acyl carrier plays a critical role in many metabolic and 
mitochondrial processes.35, 100, 101 MS/MS represents the optimal platform for developing 
CoA analysis due to its sensitivity and specificity.  Also, when subjected to collision-
induced dissociation (CID), CoA derivatives exhibit a characteristic fragmentation 
pattern, breaking at the ATP moiety, resulting in product ions with a neutral loss of 507
amu (Figure 2.1A).76, 102 Typical parent protonated molecular ions observed for 
endogenous CoASH and its derivatives in a constant neutral loss/MS experiment are 
presented in Figure 2.1B.  The use of this type of analysis not only facilitates LC-
SRM/MS method development, but also allows for more specific CoA discovery 
experiments.  However, the lack of isotopically labeled CoA has limited the development 
of comprehensive stable isotope dilution MS/MS analysis of CoA-containing compounds.   
In this chapter, our focus is in generating stable isotope labeled CoASH and short-
chain acyl-CoA species, which would not only improve our ability to study metabolism,53, 
54, 58, 103 but also aid in the diagnosis of various metabolic diseases.60-64, 104  The use of 
labeled standards is particularly important, since cellular thiols can be rapidly ox dized or 
react with both intracellular and extracellular molecules.105-107  To biosynthetically 
generate labeled CoA standards, we developed SILEC, a method similar to SILAC, 
except that a labeled vitamin, pantothenate, is used instead of labeled amino acids.93 
Unlike plants, fungi, and most prokaryotes, animals are not capable of de novo 
pantothenate synthesis.33 As a result, pantothenate is a dietary requirement and a 
necessary cell culture media supplement.  After uptake, pantothenate is converted to CoA 
through five enzymatic steps.35 By growing cells in the presence of [13C3
15N]- 
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Figure 2.1 CoA structure and LC-constant neutral loss/MS analysis. (A) Generalized 
CoA structure, showing the CID-induced neutral loss of the ATP moiety (m/z 507).  The 
substituent (R group) can include any thioester or derivative of CoA arising from 
endogenous or exogenous sources.  (B) LC-constant neutral loss/MS scans (m/z 507) of 
short chain acyl-CoA species extracted from unlabeled Hepa 1c1c7 murine hepatoma 
cells.  The extraction was performed as described in the methods section.  The precursor 
parent molecules of various short-chain acyl-CoA species are annotated in the spectrum. 
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pantothenate, the stable isotopes were incorporated into CoA (Figure 2.2) much as 
labeled lysine and leucine are incorporated into proteins using SILAC methodology.  
This allowed us not only to generate isotopically labeled CoASH, but also a wide var ety 
of acyl-CoA thioesters in a single biological system.  In this chapter, we pres nt the 
development of this method, with particular focus on optimization of growth conditions, 
scale-up, validation as well as preparation of specific CoA species, which were 
subsequently extracted and used as LC-MS internal standards in vitro as well as in mouse 
tissue.  A detailed step-by-step protocol and troubleshooting guidelines are presented in 
the following chapter. 
 
 
2.3 Materials and Methods 
2.3.1 Chemicals and Reagents.  
CoASH, acetyl-CoA, succinyl-CoA, HMG-CoA, propionyl-CoA, SSA, TCA and 
menadione were purchased from Sigma Aldrich (St. Louis, MO).  RPMI 1640 
pantothenate-omitted media was purchased from AthenaES (Baltimore, MD).  
Undialyzed FBS (uFBS), dialyzed FBS (dFBS), and charcoal-dextran stripped FBS 
(csFBS) were purchased from Gemini Bio-Products (West Sacramento, CA).  All 
solvents used were Optima grade (Fisher Scientific, Pittsburgh, PA). [13C3
15N1]-
pantothenate was purchased from IsoSciences (King of Prussia, PA). 
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Figure 2.2 Incorporation of [13C3
15N1]-pantothenate into CoA.  Enzymes:  (A) 
Pantothenate kinase (rate-determining). (B) Phosphopantothenoyl cysteine synthetase. 
(C) Phosphopantothenoyl cysteine decarboxylase. (D) Phosphopantetheine 
adenylyltransferase. (E) Dephospho-CoA kinase.  [13C] and [15N] atoms are marked in 
red. 
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2.3.2 Cell culture and extraction of short chain CoA thioesters.  
Murine hepatocytes (Hepa 1c1c7, ATCC #CRL-2026) were maintained in RPMI 
1640 media supplemented with 10% FBS, 2 mM L-glutamine, 100 units/mL penicillin 
and 100 µg/mL streptomycin at 37°C and 5% CO2.  Extraction of CoA species was 
performed using modifications to similar methods.102, 108 Briefly, cells were washed twice 
with 10 mL of ice cold PBS.  Cells were harvested by scraping into 1 mL of PBS.  A 100 
µL aliquot was saved for protein quantitation and the remainder was pelleted at 1000g.  
The cell pellet was resuspended in 1 mL ice cold 10% TCA and pulse-sonicated for 30 
sec on ice using a sonic dismembranator (Fisher), followed by a 5 min centrifugation at 
15000g.  The supernatant was transferred to a fresh tube and the pellet was discarded.  
The supernatant was purified by SPE as follows:  Oasis HLB 1cc (30 mg) SPE columns 
(Waters) were pre-conditioned with 1 mL methanol followed by equilibration with 1 mL 
water.  The collected supernatant was applied, washed with 1 mL water and finally eluted 
using 3 subsequent applications of 0.5 mL methanol containing 25 mM ammonium 
acetate.  Eluted compounds were dried down with nitrogen and resuspended in 100 µL 
5% 5-SSA. Injections of 10 µL were made for LC-MS analysis. 
 
2.3.3 LC-MS.  
Analytes were separated using a reversed phase Phenomenex HPLC Luna C18 
column (2.0 x 150 mm, pore size 5 µm) with 5 mM ammonium acetate in water as 
solvent A, 5 mM ammonium acetate in 95/5 acetonitrile/water (v/v) as solvent B and 
80/20/0.1 (v/v/v) acetonitrile/water/formic acid as Solvent C.  Gradient conditis were 
as follows: 2% B for 1.5 min, increased to 25% over 3.5 min, increased to 100% B in 0.5 
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min and held for 8.5 min, washed with 100% C for 5 min, before equilibration for 5 min.  
The flow rate was 200 µL/min.  Samples were analyzed using an API 4000 triple 
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the positive ESI 
mode.  Samples (10 µL) were injected using a Leap CTC autosampler (CTC Analytics, 
Switzerland) where they were maintained at 4°C, and data was analyzed with Analyst 
1.4.1 software.  The column effluent was diverted to the mass spectrometer from 8 min to 
13 min and to waste for the remainder of the run.  The mass spectrometer operating 
conditions were as follows: ion spray voltage (5.0 kV), compressed air as curtain gas (15 
psi) and nitrogen as nebulizing gas (8 psi), heater (15 psi), and collision-induced 
dissociation (CID) gas (5 psi).  The ESI probe temperature was 450°C, the declustering 
potential was 105 V, the entrance potential was 10 V, the collision energy was 45 eV, and 
the collision exit potential was 15 V.  Isotopic labeling using [13C3
15N1]-pantothenate 
resulted in labeled CoA and thioester derivatives with a mass shift of 4 amu.  Transitions 
employed for LC-SRM/MS analyses are shown in Table 2.1. 
 
2.3.4 Stable isotope labeling using [13C3
15N1]-pantothenate.  
Labeling of CoA and its thioesters was achieved using a procedure similar to 
SILAC except that [13C3
15N1]-pantothenate was used instead of labeled amino acids.
92  
Murine hepatocytes were cultured in RPMI media containing 1 mg/L [13C3
15N1]-
pantothenate and 10% serum (uFBS, dFBS, or csFBS).  To monitor labeling efficiency, 
cells were harvested at each passage and processed as described above.  The ratio of 
unlabeled to labeled CoASH was used to monitor labeling and to calculate absolute 
concentrations of pantothenate.  To characterize pantothenate labeling, cells wer  grown  
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Table 2.1 SRM transitions for short-chain CoA thioesters and stable isotope label d 
analogues prepared by SILEC. 
 
 
 
Compound
Parent 
(m/z)
Daughter 
(m/z)
CoASH 768.1 261.1
[13C3
15N1]-CoASH 772.1 265.1
Acetyl-CoA 810.1 303.1
[13C3
15N1]-Acetyl-CoA 814.1 307.1
Propionyl-CoA 824.1 317.1
[13C3
15N1]-Propionyl-CoA 828.1 321.1
Succinyl-CoA 868.1 361.1
[13C3
15N1]-Succinyl-CoA 872.1 365.1
HMG-CoA 912.1 405.1
[13C3
15N1]-HMG-CoA 916.1 409.1
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to confluence, washed and treated with the labeling media for 0, 1, 3, 6, 12, 18 or 24 h, 
followed by harvesting and extraction.  CoA labeling and scale-up were optimized by 
varying the type of serum (uFBS, dFBS and csFBS) as well as the concentration of 
[13C3
15N1]-pantothenate, supplemented into the labeling media.  After scale-up (as 
described below), cells were harvested by scraping and sonication in 10% TCA.  
Acidified extracts containing stable isotope labeled CoA thioesters were pool d, 
aliquoted, frozen, stored at -80°C and thawed as needed. 
 
2.3.5 Scale up of labeled CoA standards 
Cells were split 1:5, collected, and processed each day for seven days.  Although 
there was some minor variation among different CoA species, the peak level for each of 
the CoA species occurred on day 4 or 5 (appendix, Table A.2).  Therefore, a two-step 
approach was employed.  First, cells were grown in media supplemented with 10% 
csFBS and 1 mg/L [13C3
15N1]-pantothenate for three passages.  Second, the media was 
replaced on the third day of the final passage with media containing 3 mg/L [13C3
15N1]-
pantothenate and 3% csFBS.  The incubation was continued overnight; cells were then 
harvested and processed the next day.  This resulted in efficient labeling of all C A 
species to > 99.5% labeling.  Typically this was conducted using twenty plates or more. 
 
2.3.6 Validation.  
Cells from twenty plates were sonicated in 10% TCA (0.5 mL per plate), pooled 
and aliquoted into 3 fractions of 3 mL, which were subsequently stored at -80°C.  Lysates 
from [13C3
15N1]-pantothenate-labeled cells were prepared as described above and also 
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stored at -80°C.  CoASH and short chain acyl-CoA standards were also stored in 5% SSA 
at -80°C.  For the standard curve, CoA standards were thawed and diluted using 10% 
TCA, each with a final volume of 0.5 mL.  One 3 mL cell lysate aliquot was thawed each 
day of the validation and divided into six 0.5 mL aliquots.  Each of the standards as well 
as the fractions was mixed with 0.5 mL of the labeled CoA TCA lysate.  Samples wer  
processed as described above.  Intra-day and inter-day validation was performed for each 
analyte. 
 
2.3.7 Application of SILEC standards to cell culture using propionate treatment  
Propionate incorporation into propionyl-CoA in Hepa 1c1c7 cells was used as a 
model for CoA metabolism.109 Treatments were performed in 10 cm tissue culture dishes 
and cells were grown to 90% confluence and washed twice with PBS prior to treatment.  
Cells were treated in a minimal treatment media consisting of HBSS, supplemented with 
CaCl2, MgSO4, glucose and 25 mM HEPES buffer.  Propionate stocks were prepared in 
HBSS at 1 M and diluted to a final treatment concentration of 10 mM.  Control cells were 
treated with treatment media alone.  Cells were treated for 1 h and processed as described 
above.  Due to the wide disparity of CoA thioesters concentrations in treated compared 
with untreated cells, an optimal “customized” internal standard mixture was generated by 
combining the CoA extracts from untreated SILEC cells and an equal number of 
propionate-treated SILEC cells.   This internal standard contained an acyl-CoA profile 
more applicable to both experimental groups.  An equal amount of these extracts were 
added into both groups as well as the standard curve.  Experimental cells were 
maintained as described previously.   
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2.3.8  Application of SILEC standards to mouse tissues 
Snap frozen mouse livers were obtained from the Lazar lab.  Liver sections (30-
100 mg) from either fed or fasted (12 h) mice were stored at -80°C.  .8 mL ice cold 10% 
TCA was added to each tube along with 0.2 mL SILEC standards.  Samples were 
homogenized twice using a Tissuelyzer system (Qiagen) at 30 Hz, for 3 minutes, and 
subsequently centrifuged at 21000g to precipitate protein pellet.  The acid extract was 
then purified using Oasis HLB SPE columns as previously described, except two washes
with water were performed.  Standard curve samples were processed in a similar fashion.   
 
 
2.4 Results and Discussion 
2.4.1 LC-SRM/MS and CoA extraction.  
While multiple LC-MS methods have been developed to analyze CoA thioester 
species in plant74, 110 and animal tissues,70, 102 the focus of our study is using mammalian 
cell culture models, which often require increased sensitivity.75, 111  CoA and short chain 
CoA thioesters were identified in cellular extracts using a constant neutral loss scan of 
m/z 507 amu corresponding to ATP (Figure 2.1).  SRM transitions were developed for 
five unlabeled and labeled CoA thioesters (Table 2.1) in order conduct sensitive 
quantitative LC-MS analysis.   However, the SILEC technique can be readily xtended to 
any short, medium, or long chain acyl-CoA thioester by modifying the extraction 
procedure.112 Due to the similarity of the various short-chain CoA thioesters, LC-
SRM/MS analysis was employed for specific identification as well accur te and precise 
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quantification of the various CoA species without requiring absolute baseline separation 
as is required in HPLC-UV methods.66, 113 CoA standards and acid extracted acyl-CoA 
molecules from hepatocytes were separated and quantified using LC-SRM/MS (Figure 
2.3). 
 
2.4.2 Stable isotope labeling with [13C3
15N1]-pantothenate.  
Stable isotope labeled CoA thioester derivatives were generated by growin  cells 
in pantothenate-omitted media supplemented with [13C3
15N1]-pantothenate.  To verify and 
characterize the incorporation of labeled pantothenate into acyl-CoA species, cells wer  
grown in labeled media, harvested at different times, and processed (Figure 2.4).  Various 
CoA species and their heavy labeled isotopes were monitored to assess the relative 
amounts of labeling.  The ratio of labeled to unlabeled CoA was consistent throughout all 
analyzed CoA thioesters.  Labeled CoASH could be detected as early as 3 h, replacing 
approximately 4% of the CoASH in the cells every hour.  After 12 h, there appeared to be 
a labeling “plateau”, likely the result of an active or sequestered CoA pool unavailable 
for turnover. 
Like SILAC methodology, labeling efficiency is dependent on the relative 
concentration of labeled to unlabeled substrate in the media.  As such, minimizing 
unlabeled pantothenate in the media is critical for the production of pure isotopically 
labeled CoA standards.  Since circulating vitamins represent a major source of 
contaminating unlabeled pantothenate in serum-supplemented cell culture, three diffe nt 
types of sera were tested: undialyzed (uFBS), dialyzed (dFBS) and charcoal-dextran 
stripped (csFBS).  Although dFBS and csFBS are both often used in many cell culture  
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Figure 2.3 LC-SRM/MS chromatograms of short chain acyl-CoA thioesters. (A) CoA 
thioester standards (1 pmol each) and (B) acid extracted and SPE purified CoA species
from Hepa 1c1c7 cells.  
Succinyl-CoA
868.1361.1
2 4 6 8 10 12 14 16 18 200.0
1.0e4
1.8e4
2 4 6 8 10 12 14 16 18 200.0
1.0e4
2.0e4
2 4 6 8 10 12 14 16 18 200.0
1.0e4
2.0e4
2 4 6 8 10 12 14 16 18 200.0
2.0e4
4.0e4
5.3e4
2 4 6 8 10 12 14 16 18 20
Time, min
0.0
2.0e4
4.0e4
6.0e4
HMG-CoA
912.1405.1
CoASH
768.1261.1
Acetyl-CoA
810.1303.1
Propionyl-CoA
824.1317.1
A
2 4 6 8 10 12 14 16 18 200.0
5.0e4
6.8e4
2 4 6 8 10 12 14 16 18 200.00
5000.00
1.00e4
2 4 6 8 10 12 14 16 18 200.0
2.0e4
4.0e4
2 4 6 8 10 12 14 16 18 200.0
2.0e5
4.0e5
2 4 6 8 10 12 14 16 18 20
Time, min
0.0
1.0e4
2.0e4
Succinyl-CoA
868.1361.1
HMG-CoA
912.1405.1
CoASH
768.1261.1
Acetyl-CoA
810.1303.1
Propionyl-CoA
824.1317.1
B
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Stable isotope labeling of CoA thioesters in Hepa 1c1c7 cells grown in 
[13C3
15N1]-pantothenate (1 mg/L).  (A) LC-constant neutral loss/MS analysis with a 
neutral loss of m/z 507 from hepatocytes extracts after 24 h of pantothenate labeling. (B) 
Time course (24 h) of pantothenate incorporation into CoA. 
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applications to decrease inter-batch variation, dialysis uses only size filtration, while 
stripping serum with activated charcoal more specifically binds and depletes cer ain small 
molecules such as steroids,114 peptide hormones, and vitamins.115 We found that maximal 
labeling was achieved by the third passage with minimal increases in labeling with 
additional passages (Table 2.2).  csFBS was determined to be the most efficient for our 
application due to its lower pantothenate content.  The maximal achievable steady-state 
of labeled CoA represents the percentage of labeled pantothenate to total pantothenate in 
the media.  By determining the percentage of CoA that is labeled within the cells, th  
concentration of unlabeled contaminating pantothenate was calculated and determined: 
uFBS (5.8mg/L), dFBS (0.21 mg/L) and csFBS (0.091mg/L) (Table 2.3).    
 
2.4.3 Scale up and customization of stable isotope labeling of CoA and its thioesters.  
To increase the purity of the labeled CoA standards, two techniques were 
employed: (A) increasing the amount of [13C3
15N1]-pantothenate in the media, or (B) 
decreasing the amount of serum.  Decreasing the serum concentration resulted in 
significantly slowed growth characteristics, while further increases in media 
supplementation of [13C3
15N1]-pantothenate resulted in limiting returns on labeling.  By 
utilizing a two-step approach using 10% csFBS initially followed by a final incubation 
with 3% csFBS, efficient scale-up was achieved while limiting the amount of labeled 
pantothenate that was required.  A chromatogram demonstrating isotopically pure CoA 
internal standards is provided in the appendix (Figure A.1).  To generate more of a 
particular labeled CoA thioester internal standard, we treated SILEC labeled cells with 10 
mM propionate for 1 h.  After incubation these cells were harvested and processed for  
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Table 2.2 Effect of different sera on stable isotope labeling of CoA (above) and 
determination of unlabeled pantothenate content in supplemented sera.  Percentage of 
labeled CoASH in Hepa 1c1c7 cells serially passaged in pantothenate-omitted RPMI 
1640 media supplemented with 1mg/L [13C3
15N1]-pantothenate and 10% serum: uFBS, 
dFBS, csFBS.   
 
 
%Lmax = fraction of labeled CoA (max), experimentally determined (Table 2.2) 
L = labeled supplemental pantothenate (1 mg/L) 
U = unlabeled pantothenate (mg/L) 
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Table 2.3 Determination of unlabeled pantothenate in different batches of FBS and in the 
cell culture media prepared from them. 
 
%Lmax 
L 
(mg/L media) 
U 
(mg/L media) 
U 
(mg/L serum) 
uFBS 63.4% 1.0 0.58 5.8 
dFBS 97.9% 1.0 0.021 0.21 
csFBS 99.1% 1.0 0.0091 0.091 
1 2 3 4 5
uFBS 59.3 59.8 55.9 58.7 63.4
dFBS 93.5 97.6 97.7 97.4 97.9
csFBS 94.6 98.4 98.9 99.0 99.1
Passage #
S
er
um
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CoA thioesters.  We found that there was a substantial increase in the amount of 
[13C3
15N1]-propionyl-CoA in these cells (Figure 2.5) 
Other approaches to generating heavy labeled CoA species are possible, though 
less optimal.  Since CoA contains pantothenate, cysteine, and ATP, labeling with cysteine 
or a heavy labeled carbon source, would also result in labeled CoA.  One limitation of 
cysteine labeling is that this can be synthesized de novo, which would result in decreased 
isotopic purity of the compound.  Furthermore, since only a small fraction of cysteine or 
carbon from isotopic nutrient sources are incorporated into CoA, these methods are less 
efficient than the described method, where nearly all of the pantothenate is incorporated 
into CoA.  Furthermore, preparation of [13C3
15N1]-analogs avoids problems that can arise 
through the metabolic instability of deuterium and the separation of deuterium and 
protium analogs that occurs during LC-MS analysis.116 Finally, methods using stable 
isotope CoA compounds with labeled acyl moieties are limited to those in which such 
labeled thioesters are available.108 If a large number of CoA species are quantified, this 
would require labor-intensive preparation of each standard individually.  Also, labeled 
CoASH could not be produced using this methodology.  In contrast, biosynthetic 
generation of CoA thioesters provides simultaneous synthesis of every labeled thioester 
standard in a particular cell type in a naturally occurring profile in the appropriate 
concentration range to be used in the study.  Moreover, different internal standard 
mixtures could be readily generated for specific applications by treating the labeled cells 
with a precursor fatty acid to reflect more appropriate thioester concentratio s (Figure 
2.5).   
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Figure 2.5  Preparation of a specific stable isotope labeled CoA thioester stabl i otope 
standard. CoA extracts from stable isotope labeled cells (A) untreated and (B) treated 
with 10 mM propionate for 60 min.  
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2.4.4 Assay validation.  
Validation was performed on various CoA thioesters using our SILEC-derived 
internal standards (Table 2.4).  Extracted samples were quantified with and without 
SILEC standards.  Specificity was also improved since the compounds were co-eluting 
with their standards.  More importantly, it was found that using stable isotope analogs as 
internal standards provided a significant improvement in accuracy and precision when 
compared with non-identical internal standards (appendix, Table A.3).  The approach 
more commonly employed involves using a non-labeled compound that is similar, but 
distinct, from the analyte of interest as the internal standard.  There are seve al drawbacks 
to using this type of method.  First, using an internal standard that is different than the 
analyte of interest presumes that both analyte and internal standard will behaveequ lly 
throughout the assay.  While this may be a reasonable assumption for closely related 
compounds, as compounds diverge chemically, they also will show a greater disparity n 
their behavior.  Second, ESI is particularly susceptible to matrix effects, due to th  
limited amount of ionization that can occur at the source.  These effects can lead to an 
under- or overestimation of certain compounds as they co-elute in a complex mixture.77, 
78, 90  Matrix effects are non-linear and can vary dramatically throughout a gradient run, 
particularly when analyzing tissue samples.  Finally, analyte stability and loss during 
sample preparation can vary considerably for different CoA species.  Therefore, the 
assumption that the measured analyte will have the same stability as the analog internal 
standard may also lead to over- or underestimation of the compound.  Additionally, the 
stable isotope can act as a carrier for trace analytes and improve sensitivity. 
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Table 2.4 Assay validation.  Standard curves were generated by spiking increasi g 
concentrations of different CoA standards with 0.5 ml of acid extracted CoA.  Pooled 
frozen extracts from Hepa cells were thawed and mixed with internal stadard mixture 
and extracted.  Limit of quantitation (LOQ) was determined to be the level at which the 
signal-to-noise ratio was at least 5:1 compared to a blank. 
Linearity LOQ
Acetyl-CoA 0.9990 2.4% 2.6% 0.1
Succinyl-CoA 0.9996 5.6% 1.6% 0.2
CoASH 0.9966 6.8% 2.6% 0.1
Propionyl-CoA 0.9999 9.1% 13.9% 0.05
HMG-CoA 0.9939 7.1% 10.4% 0.2
 (R2)
Precision (RSD)
Intra-
batch
Inter-
batch
(pmol)
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2.4.5 Applications of SILEC standards to biological samples 
 Cells treated with 10 mM propionate for 1 h showed a 10-fold increase in 
propionyl-CoA levels as compared to control cells, with concomitant decreases in levels 
of acetyl-CoA, succinyl-CoA, and CoA (Figure 2.6).  In addition to cell culture, SILEC 
internal standards improved the precision of CoA measurements from tissues as well.  
Livers from fasted vs. fed mice showed significant differences in various short chain 
acyl-CoA species.  In particular, there was a significant decrease in the amount of acetyl-
CoA and succinyl-CoA levels, and an increase in the propionyl-CoA levels.  There was 
also an increase in CoASH, though this change was not statistically significant.  These 
data are consistent with a recently published study in fed and fasted mice, except that 
acetyl-CoA levels were increased rather than decreased in their model.  However, 
differences in diet, fasting conditions as well as mouse line may contribute to th
differences between these studies.   
 
2.5 Conclusions 
A SILEC method has been developed for generating labeled CoA and CoA 
thioester standards by adapting SILAC methodology to utilize an essential vitamin and an 
endogenous biosynthetic pathway.  Isotopically labeled substrates have been employed 
previously in tracer experiments to monitor cellular metabolic flux.94 However, our study 
has focused on the optimization and scale-up of stable isotope labeled standards with low
levels of the endogenous unlabeled analogs for use in quantitative assays.  By using 
csFBS instead of dFBS or uFBS, more effective incorporation of pantothenate was 
achieved.  The resulting SILEC methodology employing [13C3
15N1]-pantothenate 
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Figure 2.6 Changes in intracellular CoA thioester levels in Hepa 1c1c7 after propionate 
treatment:  untreated (white), 10 mM propionate for 1 h (black). CoA thioesters exract d 
from control and treated SILEC-labeled cells were combined and used as stable isotop  
internal standards in measuring short chain acyl-CoA species. * p<0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 CoA-thioester levels in fed vs. fasting mice.  Frozen mouse livers were 
processed for CoA levels using SILEC standards, n = 5 per group. 
Acetyl-CoA Succinyl-CoA CoASH Propionyl-CoA
0
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DMSO
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*
* *
*
pm
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n
Fed Fasted p value
Acetyl-CoA 26.1 12.8 2.E-04
Succinyl-CoA 9.2 5.3 5.E-04
CoASH 75.5 95.3 0.43
Propionyl-CoA 0.19 0.33 0.02
HMG-CoA 0.41 0.13 3.E-06
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(instead of labeled amino acids used in SILAC methodology) made it possible to 
rigorously quantify short chain CoA thioesters in cell culture.   
While our analysis was limited to short chain acyl-CoA species, this approach 
could be readily adapted to analyze medium or long chain CoA thioesters and other CoA-
containing species with minor modifications to the extraction protocol.112  Furthermore, 
by adapting the SILEC methodology, it could also be used to synthesize stable isotop s 
for metabolites that are derived from other isotopically labeled essential nutrients such as 
folates, riboflavin (vitamin B2), and niacin (vitamin B3).  Stable isotope labeled 
metabolites from the extracts of these cells could subsequently be used as internal
standards to more accurately quantify folate polyglutamates,117 NAD,118 or FAD.119  
Finally, the availability of labeled CoASH will facilitate the development of methodology 
for the quantification of this important mitochondrial thiol and its oxidized mixed 
disulfide derivatives such as glutathione-CoA. 
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Chapter 3: A practical protocol for the generation and application of SILEC mass 
spectrometry standards to biological samples 
 
3.1 Abstract 
SILEC was developed in Chapter 2 to generate isotopically labeled CoA and 
short-chain acyl-CoA thioesters, by modifying SILAC to include [13C3
15N1]-pantothenate 
instead of the isotopically labeled amino acids.  The lack of a de novo pantothenate 
synthesis pathway allowed for efficient and near-complete labeling of the measured CoA 
species.  This chapter provides a step-by-step approach to generating SILEC labeled 
internal standards in mammalian and insect cells, as well as how to utilize them in stable 
isotope dilution MS-based analyses. Troubleshooting guidelines as well as a list of 
unlabeled and labeled CoA species are also included.  This protocol represents a 
prototype for generating stable isotope internal standards from labeled ess ntial nutrients 
such as pantothenate. 
 
 
 
 
 
 
 
 
Portions of this chapter have been previously published (Basu SS, Blair IA. Nat Protocols, 2011).
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3.2 Overview  
 
SILEC methodology can be used to label CoA in any cell system that does not 
contain a robust de novo pantothenate synthesis pathway, including mammalian and 
insect cell lines, both of which are described in this protocol.  Hepa 1c1c7 murine 
hepatoma cells were originally chosen due to their rapid growth rates in SILEC media, 
the abundance of short-chain acyl-CoA species of interest, and relative ease in scalability.  
In this chapter, we increase the breadth of the method developed in Chapter 2 by adapting 
SILEC labeling to Drosophila S2 cells, which have even shorter doubling times and grow 
in suspension, facilitating larger scale preparations of labeled standards.  The purpos of 
this protocol is to provide a practical guide to generate stable isotope labeled short-chain 
acyl-CoA thioesters for use as internal standards in quantitative stable isotope dilution 
LC-MS assays.   
 
3.2.1 Generation of labeled CoA 
Biosynthetic generation of labeled CoA standards can be divided into four steps 
(Figure 3.1).  The objective of the first step is to label the majority of the intracellular 
CoA while still generating enough cellular material to accommodate the proposed 
experiment.  To accomplish this, cells are passaged 3-5 times in media containing 10% 
csFBS and 1mg/L [13C3
15N]-pantothenate, with unlabeled pantothenate specifically 
omitted.  By the third passage, approximately 98-99% of the CoA in the cell are 
isotopically labeled.   In the second step, the media is replaced overnight with ultra-
labeling media containing a higher concentration of labeled pantothenate (2-3 mg/L) and 
a lower concentration of serum (0-5%).  This both increases the concentration of labeled  
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Figure 3.1 General scheme for Stable Isotope Labeling by Essential nutrients in Cell 
Culture (SILEC). (1) Expansion.  Cells are serially passaged and expanded in the 
presence of labeled pantothenate.  (2) Ultra-labeling.  Media containing less serum and 
more labeled pantothenate is used to increase purity of labeled CoA.  (3) Customization 
(optional).  Labeled cells are subjected to different biological, pharmaceutical or 
toxicological exposures to modify the CoA derivative profile within the cells.  (4) 
Extraction.  Cells are lysed and pooled together to generate a SILEC CoA internal 
standard mix with a more global CoA profile.  (5) SILEC spike-in.  Equal amounts of 
SILEC internal standards are spiked into CoA standards, as well as in vitro, tissue or 
clinical samples.  (6) Sample extraction.  Standards and samples are subjected to the same 
sample extraction procedures. (7) LC-MS analysis.  CoA species are sepaated and 
analyzed by LC-SRM/MS.  Co-eluting SILEC standards are used to confirm the identity 
and normalize for the different CoA species.  
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pantothenate in the media, while decreasing the level of the contaminating unlabeled 
pantothenate from the serum.  While serum-free culture could further decrease unlabeled 
pantothenate levels, such conditions can also negatively affect growth, viability nd 
metabolic characteristics of cells in culture.120-122 Therefore, an optimal level of serum 
must be determined to balance the benefits of increased labeling, while still maintaining 
cellular characteristics.  At this point, the CoA species from a repres ntative plate can be 
sampled to determine labeling efficiency and CoA profile using LC-neutral loss scan of 
m/z 507.  If the desired CoA species can be identified and measured, the third step is not 
necessary.  However, if one or more of the labeled CoA species of interest are below a 
reproducibly quantifiable level, a customization step may be necessary.  This can be
accomplished in multiple ways.  First, labeled cells can be supplemented with a paricular 
fatty acid, such as propionate or β-hydroxybutyrate (BHB) which is then taken up by the 
labeled cells to generate a higher percentage of that particul  fatty acyl-CoA (Figure 3.2).  
In addition, cells can be subjected to different biological perturbations or toxicolgi al 
insults to increase and decrease particular CoA species or to generate xenobiotic-CoA 
adducts such as menadione-CoA (Figure 3.3).  The CoA species in these cells can then be 
extracted and pooled together to generate a SILEC reference metabolome, containing a 
more appropriate or more global CoA profile for the experiment.  Alternatively, the 
cellular lysate can be hydrolyzed with a strong base, and the resulting [13C3
15N1]-CoASH 
can be generated.  This can be further purified and used to synthesize a particular CoA 
derivative.73, 123-125 
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Figure 3.2 SILEC labeling and “customization” of CoA metabolome. (A-C) LC-neutral 
loss/MS scans (m/z 507) of acid extracted acyl-CoA species in SILEC-labeled Hepa 
1c1c7 cells that were: (A) untreated, (B) treated with 10mM propionate for 1 h, or (C) 
treated with 10 mM BHB for 1 h.  (D-F) LC-neutral loss/MS scans (m/z507) of acid 
extracted acyl-CoA species in Drosophila S2 cells that were: (D) untreated, (E) treated 
with 10 mM propionate for 1 h, or (F) treated with 10 mM BHB for 1 h. The precursor 
ion masses of various labeled short chain acyl-CoA species can be identified: [13C3
15N]-
acetyl-CoA (m/z 814), [13C3
15N]-succinyl-CoA (m/z 872), [13C3
15N]-CoASH (m/z 772), 
[13C3
15N]-propionyl-CoA (m/z 828), [13C3
15N]-BHB-CoA (m/z 858).  These “customized” 
CoA extracts can be pooled together to generate a more comprehensive CoA profile. 
 (A) (B) (C) 
(D) (E) (F)  
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Figure 3.3 Biosynthetic generation of isotopically labeled menadione-CoA.  (A) LC-
neutral loss/MS scan (m/z 507) of acid-extracted CoA species from SILEC-labeled Hepa 
1c1c7 cells treated with 20 µM menadione for 1 h. (B) LC-SRM/MS chromatogram of 
[13C3
15N]-menadione-CoA (m/z 942  435) derived from the same extract.  Extraction 
and analysis were performed as specified.  By spiking this extract into experimental 
samples, this isotopically labeled analyte can be used as an internal stand rd for 
quantifying unlabeled menadione-CoA.  
m/z  942  435 
 (A) 
(B) 
O
O
CoA
[13C3
15N]- 
Menadione- 
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3.2.2 Application of SILEC standards to biological samples 
The cellular extracts containing the SILEC-labeled CoA internal standards c n be 
applied to biological samples and used to normalize for the CoA species of interest 
(Figure 3.1).  These biological samples can include cultured cells, tissue sample , or 
clinical samples of obtainable cells such as fibroblasts, lymphocytes or platelets.  In each 
case, a constant amount of SILEC standards are spiked into the samples at an early point 
during sample processing; to scraped cells for in vitro experiments, to snap-frozen or 
lyophilized tissues for in vivo experiments or into purified cells such as lymphocytes or 
platelets for clinical studies.  In addition to spiking the samples, the same amount of 
SILEC-labeled CoA internal standards are also spiked into known quantities of unlabeled 
CoA standards to generate a standard curve.  Both biological samples and unlabeled CoA 
standards can then be extracted using SPE and analyzed by LC-MS.  The peak area of 
each unlabeled standard is divided by the peak area of the corresponding SILEC internal 
standard analog to generate a standard curve of standards to peak area ratio.  The same 
analysis is then performed on each sample and the peak area ratio is then used to 
calculate the amount of each of the CoA species in the sample.  These amounts are then 
compared between experimental groups.  This method is comparable to the SILAP or 
SILAC “spike-in” methods that have been described previously.97, 99  The strength of 
using a stable isotope dilution MS method is not only in the specificity of CoA elution, 
but also that the labeled compounds will have the same stability as the unlabeled analyte 
of interest.  Therefore, there would be a parallel degradation of the labeled intrnal 
standard that does not affect the ratio of unlabeled analyte to labeled internal stand rd.  
For this reason, absolute quantification of the labeled internal standards is unnecessary. 
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3.2.3 Additional considerations for modifying SILEC approach 
Although this protocol specifically addresses the ability to generate iso opically 
labeled short chain acyl-CoA species, this can be modified to include other CoA species 
or adapted for other essential nutrients.  There are several general aspectsto consider if 
such an approach is taken.  First, limitations of the SILEC approach are similarto those 
encountered with SILAC labeling in that a biological system is used to generate stabl  
isotope standards.  Although numerous labeled CoA species can be generated in a single 
system, batch-to batch variability persists even under well-controlled conditions.  If using 
a starting material other than pantothenate such as folates, it is important t use media 
and the appropriate serum that does not contain that essential nutrient.  Therefore, an 
omitted media along with a modified serum (such as csFBS or dFBS) is critical to 
generating isotopically pure standard.  Finally, finding the appropriate cell line is also 
necessary for optimization.  Since this is largely empirical, many cell lin s likely need to 
be tested to optimize scale-up and production.  A time-course should be established in 
order to determine the optimal time for harvesting from the chosen cell line, as was 
demonstrated in the Chapter 2. 
 
3.3 Materials 
• Cell line of choice (protocol written for Hepa 1c1c7 cells, ATCC #: CRL-2026 
and Drosophila Schneider 2 cells, Invitrogen) 
• Media: 
• Mammalian cells: pantothenate-omitted RPMI 1640 media (AthenaES, MD) 
• Insect cells: Schneider’s media 
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• Hank’s Buffered Salt Solution (HBSS) 
• Phosphate-buffered saline (PBS) 
• [13C3
15N1]-pantothenate (Isosciences, PA) 
• Charcoal-dextran stripped FBS (Gemini Biosciences, CA) 
• 10 cm tissue culture dishes 
• 75-cm2 tissue culture flasks 
• Cell scrapers 
• Penicillin, streptomycin 
• Glutamine 
• Trichloroacetic acid (TCA) 
• 5-Sulfosalicyilic acid (SSA) 
• Potassium hydroxide (KOH) 
• Oasis HLB 1cc (30 mg) SPE columns (Waters) 
• 10 mL conical glass centrifugation tubes 
• Nitrogen gas 
• Methanol 
• Ammonium acetate 
• Acetonitrile and water (mass spectrometry grade) 
• Formic acid  
Instrumentation: 
• Probe sonicator  
• Microcentrifuge 
• Vacuum manifold 
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• Nitrogen evaporator 
• Refrigerated autosampler  
• HPLC system with three pumps 
• Triple quadrupole mass spectrometer (API 4000 or instrument of similar 
sensitivity) 
• Computer with mass spectral computational software 
Reagent Setup: 
• Heat-inactivated csFBS.  Thaw at 37°C and heat inactivate complement for 30 
min at 55°C.  Aliquot into 50 mL fractions and store at -20°C. 
• [13C3
15N]-Pantothenate stocks.  Prepare in double distilled (dd) H2O at 1 mg/mL 
and store at -20°C. 
• Unlabeled CoA standards.  Prepare 5 mM stock solutions of acyl-CoA species in 
5% aqueous SSA.  Store in aliquots at -80°C.  Thaw when needed and avoid 
repetitive freeze thaw cycles. 
• SILEC Expansion media. Mammalian cells: Prepare pantothenate-free media 
containing 10% heat-inactivated csFBS, 2 mM L-glutamine, 100 I.U./ml 
penicillin, 100 µg/ml streptomycin and 1 mg/L [13C3
15N]-pantothenate.  Insect 
cells (S2): Prepare Schneider’s media containing 10% heat-inactivated csFBS, 2 
mM L-glutamine, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 3 mg/L 
[13C3
15N]-pantothenate.   
• SILEC Ultra-labeling media. Mammalian cells: Prepare pantothenate-free media 
containing 3% heat-inactivated csFBS, 2 mM L-glutamine, 100 I.U./ml penicilli , 
100 µg/ml streptomycin and 3 mg/L [13C3
15N1]-pantothenate.  Insect cells (S2): 
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Prepare Schneider’s media containing 3% heat-inactivated csFBS, 2 mM L-
glutamine, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 10 mg/L [13C3
15N]-
pantothenate. 
• Customization of media. Prepare HBSS media supplemented with Ca2+, Mg2+, 1 
g/L D-glucose, 25mM HEPES and the appropriate modifying compound (fatty 
acid, xenobiotic, etc.).  For example, to generate labeled propionyl-CoA, add 10 
mM propionic acid; for labeled BHB-CoA, add 10 mM BHB; for labeled 
menadione-CoA, add 20 µM menadione.  All media should be filtered and can be 
stored at 4°C for up to 3 months.  Warm media to 37°C prior to cell treatment for 
mammalian cells and to room temperature for insect cells.  
• CoA extraction reagents. 
o Extraction solution: 10% (w/v) TCA in dd H2O.  Chill on ice prior to 
experiment. 
o Elution solution: 25mM ammonium acetate in methanol. 
o Resuspension solution:  5% (w/v) SSA in dd H2O.  
o Hydrolysis solution: If pure [13C3
15N1]-CoASH is being generated, prepare 
40% (w/v) KOH in dd H2O.   
• LC-MS solvents.  Prepare, sonicate and degas HPLC solvents prior to LC-MS 
analysis.  Use solvents of mass spectrometry grade (Fisher Optima grade solvents 
are used for our analysis) 
o Solvent A: 5mM ammonium acetate in water 
o Solvent B: 95:5 ACN:H2O 5mM ammonium acetate in water 
o Solvent C: 80:20:0.1 ACN:H2O:formic acid 
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3.4 Procedure  
Generating labeled CoA standards 
1. Thaw frozen cells directly into SILEC expansion media.   
2. For Hepa 1c1c7 (adherent) cells, allow cells to reach confluency (3-4 days), w sh 
two times with PBS, trypsinize and split 1:5 into SILEC expansion media.  For S2 
(suspension) cells, when cells have reached approximately 1x107 cells/ml, split 
into a new flask containing SILEC expansion media at a concentration of 2x106 
cells.   
3. Repeat step 2, passaging cells in SILEC expansion media three more times. At 
this point, CoA species should be greater than 98% labeled.  If cell growth or 
morphological characteristics are significantly affected, see troubleshooting guide: 
Perturbation of cell growth kinetics by SILEC media. 
Pause point: Harvest and freeze down one plate of labeled cells in SILEC expansion 
media containing 10% DMSO.   These cells can be thawed to seed future SILEC 
expansions. 
4. After the fourth passage, allow cells to reach confluency or 1x107 cells/mL. 
5. Ultra-labeling step: Wash cells with 10 mL PBS and replace with SILEC Ultra-
labeling media and incubate for 24 h. 
 
Testing of SILEC labeling 
Short chain acyl-CoA acid extraction: 
6. Harvest one plate of cells by scraping gently into media and spin down at 1000g.
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7. Resuspend cells in 1 mL ice-cold extraction solution (10% TCA) 
8. Sonicate cells for 30 sec on ice in a pulsatile manner. 
9. Spin sonicated cell lysate at 15000g for 5 min to precipitate protein pellet. 
 
Solid phase extraction (SPE): 
10. Using a vacuum manifold, condition Oasis HLB SPE columns with 1 mL of 
methanol. 
11. Equilibrate with 1 mL water. 
12. Load acid extracted lysate (supernatant) to columns. 
13. Wash column with 1 mL water. 
14. Elute CoA compounds into fresh tube by applying three subsequent applications 
of 0.5 mL elution solution. 
15. Dry samples under nitrogen. 
16. Re-suspend in 50 µL of 5% SSA. 
 
LC-MS analysis: (see Chapter 2 for specific LC-MS parameters) 
17. Using the LC-MS specifications in Figure 2, perform a CID neutral loss scan of 
507 amu, scanning a parent mass range of m/z 750 to m/z 1200. Sample injections 
of 10 µL should be used for analysis. 
18. Characterizing CoA SILEC Profile: Generate a m/zlist from the neutral loss scan 
and compare them against a m/z list of CoA species (Appendix), and prepare a 
SRM experiment for each of these parent ions and their respective product ions. 
The singly charged protonated molecule should be used for the parent CoA while 
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the associated product ion of 507 amu lower than the parent protonated molecule 
should be used.  For example: acetyl-CoA has a parent protonated molecule of 
m/z 810.1 and a product ion at m/z 303.1 while [13C3
15N1]-acetyl-CoA has a parent 
protonated molecule of m/z of 814.1 and a product ion at m/z 307.1 
19. Determining labeling efficacy: Re-inject and analyze the sample usingthe LC-
SRM/MS method, monitoring both the labeled and unlabeled channels to 
determine the amount of unlabeled CoA remains for each acyl-CoA. 
20. Confirmation of acyl-CoA species: To confirm the identity of the labeled CoA 
species, spike extracted SILEC standards with a mixture of the CoA thioesters of 
interest (1 pmol each) and repeat the LC-SRM/MS analysis.  The labeled and 
unlabeled compounds should co-elute.  This is particularly important when 
multiple peaks arise or if there are multiple isobaric CoA species with similar 
parent and product ions. 
 
Harvesting  
21. If there are certain CoA species you are interested in that are not represented in 
the mixture, further steps may need to be taken (see “Generating customized 
SILEC standards”).  In the case of incomplete labeling, systematic 
troubleshooting may be necessary (See troubleshooting section: Inc mplete 
labeling).  If one or more CoA thioesters of interest are not represented, continue 
on to step 23 to generate “customized” SILEC standards.  If labeling is complete 
(> 99% labeling) and CoA profile is satisfactory, perform CoA extraction for all 
plates (steps 7-10). 
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22. Pool together acid soluble SILEC extracts, label batch and freeze at -80°C in 10 
mL aliquots. 
Pause point: The pooled acid soluble extracts contain the SILEC standards that will later 
be spiked into cell or tissue samples.  These standards can be stored indefinitely at -80°C, 
but should be spiked into a new standard curve for each analysis.  Avoid repetitive 
freeze-thaw cycles. 
 
Generating customized SILEC standards 
23. (Continued from step 21) Wash half of the plates 2X with PBS. 
24. For the washed plates, replace with customization media and incubate washed 
plates in treatment media for 1 h. 
25.  Test labeling using steps 17-20  
26. After incubation, harvest and extract CoA from all plates (steps 7-10) and pool 
together.  This pooled extract should contain a SILEC CoA profile with increased 
levels of the species of interest. 
CRITICAL STEP:  It should be noted that using exogenous biological and toxicological 
stimuli to change the CoA profile in a given cell types is largely empirical and needs to 
be optimized for different cell systems and conditions.  Prior to scaling up, optimization 
can be performed in unlabeled cells, though should be confirmed in labeled cells as well.
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Producing purified [13C3
15N]-CoASH 
27. (Continued from step 5) After overnight incubation in ultra-labeling media, 
perform steps 6-9 for all plates and pool together acid soluble lysates, which 
contain CoASH and short chain acyl-CoAs. 
28. Adjust pH of lysate to ~13 with 40% KOH w/v.  (Add 500 µL KOH to 5 mL TCA 
extract) and incubate at room temperature for 1 h. 
29. Adjust pH of lysate to 6 with formic acid. 
30. Purify labeled CoA using either preparative HPLC (monitor UV wavelength 254) 
or SPE extraction using previously described procedures. 
31. Dry down hydrolyzed extract, which contain purified [13C3
15N]-CoASH.  This 
product can now be used to chemically synthesize a particular CoA derivative.73, 
123-125 
  
Utilizing SILEC standards for CoA analysis 
32. Thaw an adequate amount of previously generated acid-extracted SILEC CoA 
internal standard mixture.  Generally, 1 mL of internal standard mixture is needed 
for every 5 samples.  After thawing, mix thoroughly by vortex-mixing and leave 
on ice. 
CRITICAL STEP:  It is important to determine the amount of labeled SILEC CoA 
standard needed prior to the experiment.  If multiple batches are necessary for a 
single experiment, these batches must first be pooled together prior to application to 
samples/standard curve.  Due to the biosynthetic nature of SILEC generatio, there 
can be significant batch-to-batch variability and likewise, using different batches of 
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labeled internal standards in different samples of the same experiment can lead to
erroneous measurements.    
33. To prepare standard curve samples: thaw and mix equal concentrations of 
unlabeled  CoA standards of interest creating a master mix, and perform two-fold 
serial dilutions, from 1 µM down to approximately 10 nM, in extraction solution 
(10%TCA).  Mix 50 µL of each dilution with 0.75 mL extraction solution and 0.2 
mL of thawed SILEC CoA internal standard extract (for a final volume of 1 mL) 
and vortex.  This will generate a standard curve from approximately 100 fmol to 
10 pmol of each CoA standard on column. 
34. To prepare experimental samples: add 0.8 mL ice cold TCA along with 0.2 mL of 
the same SILEC internal standard mixture to harvested cell pellets, snap-frozen or 
lyophilized tissues, or purified extracted cells (platelets, lymphocytes, fibroblasts, 
etc.) 
35. For cell samples, sonicate for 30 sec on ice in a pulsatile manner.  For tissue 
samples, homogenize according to standard protocols.  In either case, perform the 
same processing step for the standard curve samples as well. 
36. Spin processed acid extracted lysate at 15000g for 5 min to precipitate protein 
pellet. 
37. Perform SPE extraction of CoA species as previously described (steps 10-16).
38. Re-suspend samples in 50 µL 5% SSA. 
PAUSE POINT: Samples and standards can be immediately analyzed or frozen at -80°C 
for future analysis.  Since the SILEC CoA internal standards are included, effcts on 
sample stability should be reflected in the internal standards as well. 
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39. For analysis, inject 10 µL from each sample or standard mix and perform LC-
MS/MS analysis using selected reaction monitoring (SRM) mode developed 
previously. 
40. From the raw data, develop a standard curve for each of the CoA species, with the 
x-axis as the known amount of injected standard and the y-axis as the ratio of 
unlabeled to labeled integrated peak areas.   
41. Use the regression line from this standard curve to calculate the amount of each 
CoA thioester in samples. 
 
TIMING 
Typical times used in our laboratory for the various steps are as follows: 
SILEC labeling: 
• Expansion: 12-16 days 
• Ultra-labeling: 1 day 
• Testing of labeling: 3 h 
• Customization: 1 h to 12 h 
• Testing of labeling: 3 h 
• Harvesting and Extraction: 30 min 
Application of internal standards 
• Sample preparation: approximately 1 h 
Analysis: 30 min per sample.  One day per experiment, total time: 15-20 days. 
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3.5 Troubleshooting 
3.5.1 Perturbation of cell growth kinetics by SILEC media.   
Changes in cell media components may affect a number of cell growth parameters 
such as doubling times, cell viability, adherence and morphological characteristics.  
While slightly slower cell growth is expected with SILEC media, if there is severely 
deranged cell growth or morphological changes, media components should be serially 
investigated.  Serum.  While serum is necessary for many cell lines, the lack of serum 
standardization and lot-to-lot variability makes it very challenging to reproducibly scale-
up many biosynthetically-generated compounds.  Charcoal-stripping is commonly used to 
standardize serum and csFBS is the optimal serum for our purposes as it dramatically 
reduces unlabeled pantothenate, which can contaminate the labeled CoA pool.  In 
addition to removing pantothenate, however, charcoal-stripping also removes a number
of other serum components including hormones, growth factors and other B vitamins, 
which can also negatively affect cell growth.114, 115 One method to overcome this is by 
either increasing the amount of csFBS or using dFBS during the expansion stage, which 
may be enough to overcome these effects.  Although dFBS would slightly increase th  
level of unlabeled pantothenate, it still has considerably less pantothenate than undialyzed 
serum.  This may improve cell growth during the expansion phase.   If it is found, 
however, that dFBS is necessary during the ultra-labeling step, the concentration should 
be substantially reduced and the concentration of pantothenate should be increased to 
lower the percentage of unlabeled pantothenate in the serum.  If both csFBS and dFBS 
are prohibitive to cell growth, and uFBS is necessary, a different cell line should be 
considered as the high level of residual pantothenate in uFBS would be difficult to 
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overcome by simply adding more labeled compound.  Other media components.  
Commercial services are available for the production of specialty media such a  
pantothenate-omitted RPMI 1640 media, which is used in our protocol.  However, should 
you choose to prepare your own SILEC media, make sure all components are dissolved 
and that your cells show similar growth characteristics when this media is supplemented 
with standard FBS and the same concentration of pantothenate.  Since certain media 
components can also degrade over time, prepared media should be kept at -20°C for long 
term storage.  Finally, contamination with mycoplasma can slow cell growth.  Therefore, 
thaw fresh cells or perform simple tests for mycoplasma to eliminate this possibility. 
 
3.5.2 Incomplete labeling.   
As previously mentioned, a critical aspect to biosynthetic generation of labeled 
standards is minimizing the unlabeled fraction.  Typical SRM chromatograms of CoASH 
harvested from [13C3
15N1]-pantothenate-labeled cells are provided in Figure 3.4.  Figure 
3.4A shows an example of insufficient labeling, with greater than 5% of the CoASH 
unlabeled, while Figure 3.4B depicts CoASH from a SILEC batch with more complete 
labeling (less than 1% unlabeled).  There are three underlying causes for incomplete 
labeling: (1) contaminating unlabeled pantothenate in the media, (2) unlabeled 
pantothenate in the [13C3
15N]-pantothenate stock, and (3) insufficient turnover of 
pantothenate or CoA pool within the cell line.  First, determine if there is contaminaing 
unlabeled pantothenate in the media, as this is the most likely cause of the incomplete 
labeling.  For mammalian cell culture, if the pantothenate-omitted media was 
commercially prepared, verify that pantothenate is not in the formulation.  If thiswas  
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Figure 3.4 Comparison of complete and incomplete labeling. LC-MS (SRM) 
chromatograms of CoASH harvested from [13C3
15N1]-pantothenate-labeled cells.  Both 
unlabeled CoASH (m/z 768  261) and [13C3
15N1]-CoASH (m/z 772  265) 
chromatograms are presented to illustrate (A) sub-optimal labeling (>5% unlabeled), and 
(B) near-complete labeling (<1% unlabeled).  Extraction and analysis were performed as 
specified in the protocol. 
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prepared in house, verify that the base nutrient mix you are using does not contain any 
pantothenate.  For insect cell culture, Schneider’s media contains yeast extr c , which 
contains a variable, though significant level of different B vitamins, including 
pantothenate.  For this reason, a higher concentration of labeled compound is needed for 
insect SILEC preparation.   
If there is incomplete labeling in insect cells, it could very well be coming from 
increased levels of pantothenate in the yeast extract (yeastolate).  To overc me this, the 
ultra-labeling step can be performed with HBSS media overnight containing 4 mg/L 
labeled pantothenate which should increase labeling to greater than 99%.  More likely, 
however, the unlabeled pantothenate is originating from the csFBS.  While there should 
be less than 0.1 mg/L of pantothenate remaining in the csFBS93 (resulting in an effective 
0.01mg/L in media containing 10% serum), it is possible that a particular lot of serum 
may have more, or that a higher concentration of serum is needed for a particular cell line.  
Adding additional labeled pantothenate to the media should overcome this problem.  If 
this is a newly occurring problem, check the lot of the csFBS, as lot-to lot variability can 
exist for serum.  If a particular lot of csFBS has worked in the past, it may be worth 
ordering several bottles of this for future use.  The serum can be frozen down and stored 
at -20°C for long-term storage.  The second possibility is that the stock itself is 
contaminated with unlabeled pantothenate.  This can be assessed by performing mass 
spectral analysis of the labeled stock.  To do this, reconstitute a small amount of the 
labeled pantothenate stock and using flow infused syringe injection and SRM analysis.  
The relative ratio of labeled to unlabeled pantothenate represents the maximal purity that 
the CoA can be labeled.  If this is not acceptable, another source of labeled pantothenate 
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should be sought.  For our experiments, we found that the isotopic purity of the stock was 
greater than 99.5%.  Finally, the last problem that can arise, particularly with suspension 
culture is that a certain amount of the unlabeled compound is not turning over and 
remains in the cellular pool due to cell death or senescence.  This is more of a problem 
with SILAC protocols because different proteins turn over at various frequencies ad 
salvage pathways of particular amino acids may cause these unlabeled species to continue
to propagate in culture.  For CoA species, this turnover is greater and more than 50% of 
the CoA can turnover in the cell in 24 h,93 although different CoA species may not 
turnover as rapidly.  To overcome this problem, simply passage the cells two or three 
more times in the expansion media.  If the cells are being split 1:3, less than 0.5% of the 
original cell mass will remain after 5 passages.  While this may add an aditional week to 
the expansion phase, this would replace at least 99.5% of the original cell mass and 
likewise the original unlabeled CoA.  Finally, batch-to-batch variability can arise from 
the biological variability of cells in different stages of the cell cycle.  This effect can be 
overcome by synchronizing cells with serum-free media prior to the final step of labeling. 
 
3.5.3 Problems in sample preparation and LC-MS 
SPE.  Oasis HLB columns (Waters) have been found to be optimal for short-chain 
acyl-CoA extraction, though other methods such as liquid-liquid extraction could be used 
as well.67, 93 However, when the experiment involves more complex biological matrix 
such as in tissue samples, or if a larger amount of biological material is being usd (to 
measure lower abundance analytes), a greater matrix effect may be observed.  In our own 
experience, we have extracted CoA species from liver, brain and adipose tissues.  Brain 
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and liver tissue contain abundant acyl-CoA metabolites, while adipose tissue was found 
to contain significantly less CoA content, likely due to the decreased cellular content per 
unit weight of tissue.  Also, after homogenization and centrifugation of the adipose tissu , 
a significant layer of fatty tissue remained on the top of the acid extract.  Therefore, the 
aqueous layer was transferred to a fresh tube, avoiding the lipid layer, and centrifug d 
again prior to SPE extraction.  In each case, repeating the SPE washing step (with water) 
one or two times may help.  Also, using a molecular weight cut off filter prior to SPE 
extraction may also reduce the matrix effect, though this will increase procssing time.  
Using methanol containing concentrated ammonia may improve elution for all 
extractions.67   
LC.  While acyl-CoA analysis is generally robust, repeated injections of cell and 
tissue extracts can lead to build-up of biological materials on the column, which can lead 
to distortions in peak shape.69 For this reason, we have added solvent C as a column wash 
step.  If peak distortion is occurring, increasing the wash step as well as slowing down the 
ramp time for washing can improve column performance, though this will also increase 
run times.  Also lowering the pH of this wash can also improve the ruggedness of the 
method.   
MS.  In the case of inadequate sensitivity, use acetonitrile instead of methanol in 
the mobile phase whenever possible, and decrease formic acid concentration during MS 
analysis.  Also, if LC-SRM/MS analysis is increased to include a large number of species, 
a proper number of analytical points may not be achieved across each peak and may lead 
to incorrect quantitation, even with internal standards.  To overcome this, SRM dwell 
time should be reduced so as to increase the number of points across the peak.  For 
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example, if measuring eight CoA species along with their internal standards (16 analytes 
total), using dwell times of 80-100 milliseconds may be acceptable.  However, if th  
number of analyzed CoA are increased to 20-30 species (40-60 total), shorter dwell times 
(20-30 ms) may be necessary to achieve enough points across the peak.  Also, dividing 
up the analysis into shorter segments can allow for longer dwell times. 
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Chapter 4:  Development of LC-MS method to monitor CoASSG and its relevance 
to mitochondrial oxidative stress 
4.1 Abstract 
Despite technical developments in measuring reactive species in the mitochondria, 
few markers of mitochondrial oxidative stress are currently available.  It has been 
previously reported that the ratio of CoASH to CoASSG can be used as a marker of 
intramitochondrial oxidative stress.   However, currently analytical methods lack 
adequate sensitivity for rigorous measurements of CoASSG in cell culture.  In this
chapter, we present a novel LC-SRM/MS method to measure CoASSG.  To accomplish 
this, CoASSG was first synthesized from CoASH and GSSG.  SILEC methodology was 
used to generate isotopically labeled [13C3
15N1]-CoASSG to be used as an internal 
standard for measuring this compound from cell culture.  Menadione and rotenone, both 
known to generate mitochondrial ROS, were applied to murine heptatoma cells (Hepa 
1c1c7) and intracellular levels of CoASH, CoASSG and various short chain acyl-CoA 
thioesters were quantified using this method.  Menadione was found to significantly 
increase CoASSG and decrease CoASH, the latter likely resulting from arylation of 
menadione and sequestration of the CoASH pool.  Although rotenone had a minimal 
effect on CoASSG levels, it had a dramatic impact on other CoA thioesters levels at 
much lower doses, a finding which is further explored in the following chapter. This 
methodology allowed more rigorous and sensitive measurement of CoASSG and will 
allow further exploration into its mechanism of formation, as well as aid in finding 
biomarkers for mitochondrial oxidative stress. 
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4.2 Introduction 
 Oxidative stress represents a pathological state in which cellular antioxidant 
defenses are overwhelmed by oxidative processes arising from endogenous or exogenous 
sources.126 During oxidative stress, several highly labile ROS can damage intracellulr 
macromolecules proteins, lipids, and DNA (both nuclear and mitochondrial).127-130 
Accumulation of this damage is believed to contribute to cancer, neurodegenerative 
diseases and is considered to be a central factor in aging.131-134    The mitochondria are a 
major source and target for ROS.  Although numerous reports have suggested 
mitochondrial dysfunction causes increased mitochondrial ROS generation through 
reverse electron transport,135-138 an increase in mitochondrial ROS does not necessarily 
equate to mitochondrial oxidative stress.  In fact, under normal conditions of 
mitochondrial respiration, it has been estimated that as much as 0.1 % and 0.5 % of 
oxygen consumed the mitochondria is converted to superoxide.139, 140 In addition, ROS 
play important physiologic roles in cell signaling.141, 142 Therefore, despite technical 
developments in the measurement of reactive species in the mitochondria,143 increases in 
ROS or RNS are not necessarily indicative of a pathological state of mitochondrial 
oxidative stress, for which few markers are currently available.   
  Glutathione (GSH) is a highly abundant intracellular thiol that serves not only a
major reducing agent, but also as an essential detoxifier of xenobiotics and potential 
damaging electrophiles.106 Glutathione peroxidase can detoxify intracellular H2O2, 
generating oxidized glutathione (GSSG), which can be reduced back to GSH by the 
action of glutathione reductase.  The redox potential of the cell can be assessed by 
65 
 
measuring the ratio of GSSG: GSH, which is increased during oxidative stress.  Thi  can 
result from GSH-dependent ROS detoxification pathways being compromised or 
overwhelmed.107 CoASH is an abundant mitochondrial thiol and like GSH, which can be 
oxidized to GSSG, CoASH can be oxidized to form CoA-CoA disulfide, 65 or can be 
converted to CoASSG.73 Although the exact role of this mixed disulfide is unknown, 
there is evidence that it has potent vasoconstrictive effects. 46, 50, 51 Like GSSG: GSH, the 
ratio of CoASSG: CoASH has been shown to increase during states of intramitochondrial 
oxidative stress, such as in rat models of seizures and hyperoxia,53, 55 or in response to 
certain pharmacological agents.42 However, the primary method to measure CoASSG has 
been with LC-UV, which requires relatively high concentrations of CoASSG and is 
inadequate for most practical cell culture applications.  In this chapter, we develop a 
novel LC-SRM/MS method to monitor CoASSG, along with CoASH and other CoA 
thioesters.  This assay was then used to assess mitochondrial oxidative stress generated 
by menadione, a vitamin K precursor, and rotenone, a classic mitochondrial complex I 
inhibitor, both known to generate reactive oxygen species in the mitochondria.135, 144 
 
4.3 Materials and Methods 
4.3.1. Materials  
Oxidized glutathione (GSSG), menadione and rotenone and were all purchased 
from Sigma-Aldrich (St. Louis, MO).  Remaining materials were obtained as previously 
reported.   
 
4.3.2 Synthesis and purification of CoASSG 
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CoASSG was synthesized using a method developed by Chang and Wilken.73  
Briefly, a 3 mL solution containing 1 mM CoASH and 10 mM GSSG was prepared in a 
50 mM sodium phosphate buffer (pH 6.8).  Oxygen was bubbled through the mixture at 
37°C for 3 h.  CoASSG was purified using preparative HPLC using a reversed-phase 
gradient separation Waters Xbridge C18 column (10 x 250 mm, 5 micron) on a Hitachi 
HPLC system equipped with a L-7100 pump, L-7400 UV detector (monitoring 254 nm) 
and D-2500 Chromato-Integtrator.  Solvent A was 5mM ammonium acetate in water was 
and solvent B was 5 mM ammonium acetate in methanol.  Gradient conditions (%B) 
were as follows: 4% for 3 minutes, increased to 50% over 17 minutes, to 80% over 2 
minutes, held at 80% for 3 minutes, returned to 4% over 1 min, and re-equilibrated at 4% 
for 6 minutes.  Flow rate was 3 mL/min. Eluting peaks were collected manually and 
identities of both CoASSG and CoASH were confirmed by LC-tandem MS (MS/MS) 
analysis on an API 4000 triple quadrupole mass spectrometer (Applied Biosystems). 
 
4.3.2. LC-MS 
SILEC standards were prepared as previously described in chapters 2 and 3.  LC-
MS analysis was also performed as previously described.  SRM transitions were 
determined for CoASSG (m/z 1073.1  566.1) and isotopically labeled [13C3
15N1]-
CoASSG was (m/z 1077.1  570.1).  Both transitions were added to the previously 
described SRM transitions developed for short chain acyl-CoA analysis.  Additionally, 
we monitored BHB-CoA (m/z 854.1  347.1) and [13C3
15N1]- BHB-CoA (m/z 858.1  
351.1).  A typical LC-MS chromatogram demonstrating baseline separation of BHB-CoA 
and malonyl-CoA (isobaric) is provided in the appendix (Figure A.2). 
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4.3.3 Cell culture and treatments 
 Murine hepatoma cells (Hepa 1c1c7) were maintained in RPMI media 
supplemented with 10% FBS, glutamine, penicillin and streptomycin at 37°C, with 5% 
CO2.   Menadione and rotenone stocks were made fresh in DMSO (1 mM).  When cells 
had reached 80% confluence, they were washed twice with PBS and the media was 
replaced with HBSS, containing Ca2+, Mg2+, 10 g/L glucose, 25 mM HEPES and either 
menadione (2 µM and 20 µM), rotenone (2 µM and 20 µM), or DMSO (vehicle).  After 1 
h, cells were harvested by scraping, processed and analyzed as previously described, with 
the additional SRM transitions noted above.   
 
4.4 Results 
4.4.1 Synthesis and purification of CoASSG 
CoASSG was synthesized using modifications to a previously developed 
method.73 The disulfide exchange between CoASH and GSSG resulted in the non-
enzymatic formation of CoASSG.  This was then purified by preparative HPLC-UV, 
monitoring absorption at 254 nm.  Preparative LC-UV chromatograms of GSSG alone, 
CoASH as well as the reaction mixture are provided in figure 4.1.  Four distinct peaks 
can be observed at 4.00 min (unreacted GSSG), 10.70 min, 11.56 min (unreacted 
CoASH), and 12.44 min.  The remaining two peaks (10.70 min and 12.44 min) were 
collected and concentrated with nitrogen, and a small aliquot was re-injected to confirm 
purity.  CID MS/MS revealed that peak 2 (10.70 min) was in fact CoASSG, and the 
product ion spectra for this molecule along with the product ion spectra for CoASH are  
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Figure 4.1 Synthesis and purification of CoASSG. CoASSG was synthesized by using 
thiol exchange reaction of CoASH with GSSG.  The reaction mixture was separated nd 
collected using preparative HPLC, monitoring UV absorption at 254 nm.  LC-UV 
chromatograms showing (A) GSSG alone, (B) CoASH alone and (C) reaction mixture of 
CoASH and GSSG.  Peaks were collected, concentrated and identified using CID-MS 
(Figure 4.2). 
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provided (Figure 4.2).  Like all acyl-CoA thioesters, both CoASH and the mixed disulfie 
CoASSG were shown to have their most prominent fragment ion to have a neutral loss of 
507 amu.  For CoASH, the optimal transition was 768.1  261.1 (as has been previously 
shown) while for CoASSG, the optimal transition was 1073.1  566.1.  The spectra 
found for CoASSG is consistent with a fast atom bombardment spectra previously 
published.42 These transitions were added to the previously developed SILEC method.  
Figure 4.3 shows a LC-SRM/MS chromatogram of acid extracted CoA specie from a 
mixture of SILEC-labeled and unlabeled Hepa 1c1c7 cells. 
 
4.4.2 Menadione affects CoASSG: CoASH ratio more than rotenone 
 Hepa 1c1c7 cells were treated with increasing doses of menadione or rotenone for 
1 h, and short-chain acyl-CoA species, along with CoASH and CoASSG were analyzed 
using the described methodology (figure 4.4) Rotenone did not significantly increase 
levels of CoASSG as we had originally suspected, even at 20 µM.  Menadione treatment, 
on the other hand, resulted in significant decreases in CoASH and increases in CoASSG.  
We had previously performed an experiment from chapter 3 in which we generated 
labeled [13C3
15N1]-menadione-CoA with treatment of SILEC labeled cells with 
menadione.  We have presented the LC-constant neutral loss/MS spectrum from that 
study in figure 4.5, which illustrates the increase in [13C3
15N1]-menadione CoA as well as 
a decrease in [13C3
15N1]- CoASH with menadione treatment.  In addition, changes in 
short chain acyl-CoA species were also monitored and are presented in figure 4.6. 
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Figure 4.2 Collision-induced dissociation (CID) mass spectra for CoASH and CoASSG.  
Preparative HPLC effluent corresponding to UV peaks (254 nm) were collected, 
concentrated and subjected to CID.  CID-mass spectra as well as fragmentation schemes 
for (A) CoASH (MH+, m/z 768), and (B)  CoASSG (MH+, m/z 1073).  
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Figure 4.3 LC-SRM/MS chromatograms of CoASH and CoASSG, along with SILEC-
labeled stable isotope analogs.    
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Figure 4.4 Dose-dependent effects of menadione and rotenone on CoASH, CoASSG and 
CoASSG: CoASH ratio.  Hepa 1c1c7 cells treated with rotenone and menadione (2 µM 
or 20 µM) or DMSO (vehicle) and processed for intracellular levels of (A) CoASH (B) 
CoASSG  (C) and CoASSG: CoASH.  Error bars are SEMs for n=4, * p< 0.005 
compared with DMSO.  
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Figure 4.5 LC-constant neutral loss/MS with a neutral loss of m/z 507 of SILEC labeled 
hepatocytes treated with (A) DMSO (vehicle), (B) 10 µM menadione, or (C) 20 µM 
menadione for 1 h.  The parent ions (MH+) of the observed CoA species are [13C3
15N1]-
CoASH (MH+, m/z 772), [13C3
15N1]-acetyl-CoA (MH
+, m/z 814), [13C3
15N1]-succinyl-
CoA (MH+, m/z 872), [13C3
15N1]-HMG-CoA (MH
+, m/z 916), and [13C3
15N1]-menadione-
CoA (MH+, m/z 942). 
(A) 
(B) 
(C) 
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Figure 4.6 Dose-dependent effects of menadione and rotenone on selected short-chain 
acyl-CoA thioesters.  Hepa 1c1c7 cells treated with rotenone and menadione (2 µM or 20 
µM) or DMSO (vehicle) and processed for intracellular levels of (A) acetyl-CoA (B) 
succinyl-CoA  (C) BHB-CoA and (D) propionyl-CoA.  Error bars are SEMs for n=4,   
* p< 0.005 compared with DMSO.  
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4.5 Discussion 
In this chapter, we have developed for the first time an LC-SRM/MS method to 
measure CoASSG.  Using the previously described SILEC methodology, we are also able 
to generate isotopically labeled [13C3
15N1]-CoASSG, which can be used as an internal 
standard for measuring this compound from cell culture.  This methodology allows more 
rigorous as well as sensitive analysis of CoASSG in cell culture, where lower 
concentrations of CoA species limits the application of currently available analytical 
methods.  As CoASSG: CoASH ratio is a purported measure of intramitochondrial 
oxidative stress, we treated cells with agents known to cause oxidative stress in the 
mitochondria. Our assay has revealed that menadione, but not rotenone, causes a 
significant increase in CoASSG, particularly at higher doses.   
In addition to increasing intracellular levels of CoASSG, menadione caused 
decreases in CoASH levels, likely due to arylation of CoASH, as thiols are known to 
react readily with redox cycling quinones.145 Additionally, in chapter 3 we demonstrated 
the generation of [13C3
15N1]-menadione-CoA internal standards by treating SILEC 
labeled cells with menadione.  In figure 4.5, we presented the LC-constant neutral 
loss/MS spectrum from that study, which illustrates the increase in [13C3
15N1]-menadione 
CoA as well as a decrease in [13C3
15N1]- CoASH with menadione treatment.  Though this 
was a qualitative rather than a quantitative assessment, a substantially larger m/z 942 
peak (corresponding to [13C3
15N1]-menadione CoA) is seen with 20 µM compared to 10 
µM menadione treatment, as well as a much more substantial decrease in [13C3
15N1]- 
CoASH.  A more thorough quantitative dosing analysis to assess the effectso  menadione 
treatment on both menadione-CoA levels and decreases in CoASH levels is needed.  This 
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increase in CoASSG could be a result of the detoxification of menadione, from increased 
mitochondrial oxidative stress, or a combination of both processes.  Although rotenone 
did not appear to increase CoASSG levels significantly, it did, however, decrease 
intracellular levels of CoASH, succinyl-CoA and propionyl-CoA and increased BHB-
CoA levels even at 2 µM.  Further exploration of these changes in human cell lines are 
described in the following chapter. 
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Chapter 5:  Rotenone-mediated changes in intracellular CoA thioester lev ls: 
implications in mitochondrial dysfunction 
5.1 Abstract 
Rotenone is a natural organic pesticide and potent complex I inhibitor shown to 
cause Parkinson-like neurodegeneration in rodents and has recently been linked to PD in 
humans.  In this chapter, rotenone-mediated effects on intracellular levels of arious CoA 
thioesters were monitored using a stable isotope dilution LC-MS methodology.  LC-
SRM/MS analysis with SILEC standards were performed to rigorously quantify dose-
dependent effects of rotenone on intracellular short chain acyl-CoA species in various
human cell lines, including neuroblastoma (SH-SY5Y), hepatoma (HepG2) and 
bronchioalveolar carcinoma (H358) cells.  To further characterize the temporal nature of 
these changes in a neuronal cell type, a time course study was performed in SH-SY5Y 
cells.  Finally, stable isotopic tracer analysis using [U-13C6]-glucose was performed in 
these cells in the presence or absence of rotenone.  Rotenone induced a dose-dependent 
decrease in succinyl-CoA and increase in BHB-CoA in all three cell lines.  Isotopic tracer 
analysis revealed that rotenone inhibited [U-13C6]-glucose-derived acetyl-CoA and 
succinyl-CoA biosynthesis in SH-SY5Y neuroblastoma cells.  These changes may reflect 
compensatory metabolic changes in response to rotenone.   
 
 
 
 
Portions of this chapter have been previously published (Basu SS, Blair, IA. Chem Res Toxicol, 2011).
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5.2 Introduction 
 
Numerous studies have suggested a link between pesticide exposure and PD, 146 
particularly to rotenone and paraquat, two naturally occurring organic pesticide.  A 
recently published nested case-control study demonstrated a 2.5 fold increase in the 
relative risk of developing PD amongst farmers exposed to either rotenone or paraquat.147 
Although both pesticides are mitochondrial toxins, they appear to have distinct 
toxicological mechanisms.25, 148-150 The focus of this chapter is to explore the effect of 
rotenone on central metabolic pathways in the cell.151, 152  The highly lipophilic nature of 
rotenone allows it to enter the blood brain barrier, freely cross cellular membranes and 
accumulate in subcellular organelles such as the mitochondria. Once in the mitochondria, 
rotenone is known to bind to complex I (NADH-ubiquinone oxidoreductase), the first 
enzyme complex of the mitochondrial respiratory electron-transport chain.  Binding of 
rotenone to complex I prevents the transfer of electrons from iron sulfur clusters to 
ubiquinone,135, 153 affecting oxidative phosphorylation and generating potentially 
damaging ROS.138, 140, 154 Chronic, low dose administration of rotenone in rats has been 
shown to result in selective nigrostriatal degeneration and formation of α-synuclein-
positive cytoplasmic inclusions (similar to Lewy bodies) in nigral dopaminergic neurons, 
resulting in neurodegenerative features similar to those seen in PD.26, 155, 156 Although the 
majority of research has focused on rotenone-mediated complex I inhibition and ROS 
formation, rotenone has been shown to have effects independent of complex I 
inhibition,157 and also induces significant metabolic alterations both in vitro and in vivo.  
Technological developments in both MS and nuclear magnetic resonance (NMR) have 
produced a growing number of metabolomic assays to assess changes in intracellular nd 
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extracellular metabolites.158, 159  Using these methodologies, in vitro treatment with 
rotenone was found to induce significant and unique changes in a number of cellular 
metabolites, including various Krebs cycle organic acid intermediates as well as 
intermediates and end-products of other major bioenergetic pathways.160, 161  
In this study, we further explored metabolic changes induced by rotenone by 
analyzing its effects on intracellular levels on various short chain acyl-CoA thioesters, 
which are known to be involved in a number of metabolic pathways.100  To accomplish 
this, we used stable isotope dilution LC-MS methodology, which allows more rigorous 
quantification for biomarkers and endogenous metabolites,91, 93 using the methodology 
described in Chapters 2 and 3. We analyzed the dose-dependent effects of rotenone on 
intracellular levels of short chain acyl-CoA species in various human cell lines, including 
neuroblastoma (SH-SY5Y), hepatoma (HepG2) and bronchioalveolar carcinoma (H358) 
cells.  To further characterize the temporal nature of these changes in a neuronal cell type, 
a time course study was performed in SH-SY5Y cells.  Finally, stable isotopic tracer 
analysis using [U-13C6]-glucose, [1,2-
13C2]-acetate, and [
13C3
15N1]-pantothenate was 
performed in these cells in the presence or absence of rotenone.  By monitoring the 
isotopomer distribution pattern in the measured CoA species, the fate of the labeled 
atoms and consequently their flux through different metabolic pathways was assesed.   
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5.3 Materials and Methods 
5.3.1 Materials 
[1,2-13C2]-acetate was purchased from Cambridge Isotopes (Andover, MA).  All 
other materials used in this chapter were obtained as previously reported.   
 
5.3.2 Generation of stable isotope labeled CoA internal standards 
Stable isotope CoA and CoA thioester internal standards were generated as 
described in chapters 2 and 3, with minor modifications as follows.  After 30 plates of 
Hepa 1c1c7 cells were ultra-labeled (overnight incubation in with 3% csFBS and 3 mg/L 
[13C3
15N1]-pantothenate), 10 plates were treated with 10 mM propionate, 10 plates were 
treated with 10 mM BHB, and 10 plates were left untreated for 1 h.  Cells were then 
harvested and SILEC CoA species were harvested and extracted as describe .  TCA 
extracts from all three groups were pooled, aliquoted, frozen, and stored at -80°C. 
 
5.3.3 Cell culture and rotenone treatments 
HepG2 and H358 were maintained in RPMI 1640 media and SH-SY5Y cells were 
maintained in 1:1 F12:DMEM, each media supplemented with 10% FBS, 2 mM L-
glutamine, penicillin and streptomycin.  Cells were incubated at 37 °C and 95% humidity 
with 5% CO2.  Rotenone solutions in DMSO were freshly prepared prior to treatment.  
Serial dilutions of rotenone were made for dosing and time course studies and treatments 
were performed when cells were approximately 80% confluent and added directly to the 
plate (DMSO < 1% volume).  Control cells were treated with an equal amount of DMSO 
containing no rotenone.  For dosing study, cells were treated for 1 h prior to harvesting.  
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For time course study, SH-SY5Y cells were treated in the same manner, and harvested at 
1, 2, 4, and 6 h after treatment. 
 
5.3.4 Extraction and measurement of CoA using SILEC standards 
Analyses of CoASH and CoA thioesters were performed using modifications of 
methodology previously described.  Briefly, after treatment, cells wereharvested by 
scraping, centrifuged at 500g, and resuspended in 1 mL ice-cold 10% TCA containing 
biosynthetically generated stable coenzyme A thioesters (SILEC).  Cells were then pulse-
sonicated on ice followed by centrifugation to remove protein debris.  The supernatant 
containing the short chain acyl-CoA species were purified by solid-phase extraction using 
Oasis HLB SPE columns.  The eluent was dried down under nitrogen and resuspended in 
50 µL 5% SSA.  CoA standards were processed in a similar fashion.  To determine 
approximate cell count, a parallel plate of cells split on the same day were countd.  
Stable isotope dilution LC-MS analysis was performed as previously described.   
 
5.3.5  Isotopic tracer analysis 
SH-SY5Y cells were maintained in culture as described above.  For isotopic 
tracer analysis, glucose-free DMEM media was prepared containing 10% csFBS, 
penicillin, streptomycin, glutamine and supplemented with 1 mg/L of either unlabeled 
glucose or [U-13C6]-glucose.  Cells were washed with PBS and treated for 6 h with 
labeled media containing 100 nM rotenone or DMSO (control).  After treatment, CoA 
species were extracted as previously described except without SILEC standards.  LC-MS 
methods conducted in the same manner except that in addition to the M0 CoA molecule, 
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the M1, M2, M3 and M4 isotopomer of each metabolite was also quantified.  Label-free 
cells were used to generate an isotopomer enrichment matrix for acetyl-CoA, succinyl-
CoA, BHB-CoA and CoASH.  An isotopomer array generated for each sample was 
multiplied by the inverse of the matrix generated from the label free cells to determine 
the absolute concentration of each isotopomer and presented as a percentage of the total 
isotopomers for each CoA derivative as described by Fernandez et al.162 A similar 
methodology was used to monitor labeling in Krebs cycle organic acids, which were 
extracted and derivatized with N-tert-Butyldimethylsilyl-N-methyl rifluoroacetamide 
(MTBSTFA), according to a previously published protocol.163 An LC-SRM/MS method 
was developed to measure derivatized citrate, aKG, succinate and malate along with their 
M0 to M4 isotopomers.  For acetate labeling, SH-SY5Y cells were treated in he same 
media except that instead of 1 mg/mL [U-13C6]-glucose, 10 mM [1,2-
13C2]-acetate was 
used, and cells were incubated in this media for 6 h.  For pantothenate isotopic tracer 
analysis, SILEC media supplemented with 10% csFBS and 3 mg/L [13C3
15N1]-
pantothenate was used and cells were incubated for 3 or 15 h.  In both cases, untreated 
cells were used for the background isotopomer distribution matrix determination. 
 
 
5.4 Results 
5.4.1 Rotenone dosing study  
Rotenone was found to induce a dose-dependent change in the short chain acyl-
CoA profile SH-SY5Y, HepG2 and H358 cells.  Most notably, there was a significant 
decrease in levels of succinyl-CoA (Figure 5.1A) and a concomitant increase in  
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Rotenone-mediated changes in intracellular CoA thioester levels. (A) 
Succinyl-CoA, and (B) BHB-CoA, extracted from SH-SY5Y cells, HepG2 cells, and 
H358 cells treated with rotenone for 1 h, in triplicate. Values are shown as % of the 
maximal level for each cell line. (C) Time course of rotenone-mediated changes in 
intracellular succinyl-CoA and BHB-CoA. SH-SY5Y cells were treated with 100 nM 
rotenone, harvested at time points up to 6 h, and processed for CoAs.  Error bars show 
SEMs for triplicate determinations.  Absolute levels for all measured CoA specie  are 
provided in the appendix (Table A.4). 
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BHB-CoA (Figure 5.1B) after 1 h of treatment with an IC50 of < 100 nM in all cell types.  
There were also significant changes in a number of other acyl-CoA thioesters, which 
varied among different cell types (appendix, Table A.4).  To characterize the temporal 
nature of these changes, SH-SY5Y cells were treated with 100 nM rotenone and 
harvested at time points up to 6 h and analyzed for CoA thioesters.  The observed 
changes seen in succinyl-CoA and BHB-CoA persisted for at least 6 h (Figure 5.1C). 
Overall, these results show that rotenone induces a rapid and persistent metabolic 
rearrangement in a variety of cell types, similar to changes observed during fasting.20 
 
5.4.2 Isotopic tracer analysis 
Although the observed changes indicate that rotenone induces a significant 
metabolic disturbance, absolute CoA measurements represent only a “snapshot” of this 
metabolic state.  To gain additional information on the cumulative flux through different 
pathways, cells were incubated with [U-13C6]-glucose and isotopomer distribution of the 
resulting CoA derivatives was analyzed.  [U-13C6]-glucose (M6) taken up by cells is 
converted during glycolysis into two [13C3]-pyruvates (M3), which can subsequently be 
converted by pyruvate dehydrogenase into [13C2]-acetyl-CoA (M2).  Both labeled 
carbons from acetyl-CoA are then incorporated into citrate and eventually form [13C2]-
succinyl-CoA (M2) in the first turn of the Krebs cycle.  Additional cycles can result in 
the M3 and M4 succinyl-CoA isotopomers.  It should be noted that isotopic tracer 
analysis is complex, with numerous intersecting metabolic pathways.  For our purposes, 
however, this simplified interpretation made it possible to asses major changes that were 
occurring in the cells.  SH-SY5Y cells were washed and treated with glucose-free media 
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supplemented with either unlabeled glucose or [U-13C6]-glucose with or without 100 nM 
rotenone.  The unlabeled cells were used to determine isotopic contributions of unlabeled 
CoA species to each isotopomer, which were subtracted from the labeled CoA species 
using a matrix analysis.162   
Rotenone significantly decreased the incorporation of glucose-derived carbon 
atoms into acetyl-CoA, from 23% to 5% demonstrating that rotenone inhibited the 
glucose-derived biosynthesis of acetyl-CoA (Figure 5.2A).  Interestingly, while there was 
a decrease in the % labeled acetyl-CoA, the overall concentration of acetyl-CoA did not 
change significantly (appendix, Table A.4)  Rotenone also significatly decreased the M2, 
M3 and M4 isotopomers of succinyl-CoA, indicating decreased conversion of glucose to 
succinyl-CoA.  Therefore, the decrease in absolute succinyl-CoA concentratio  was due, 
in part, to decreased glucose-derived flux through the Krebs cycle (Figure 5.2A).  Lastly, 
there was no isotopic labeling of CoASH, confirming that the labeling occurred only in 
the acyl moiety.  The decreased flux of glucose-derived carbons was also observed in the 
Krebs cycle organic acids (Figure 5.2B), confirming the decrease in glucose-derived 
carbons in the Krebs cycle.  There was also a total relative decrease of labeled carbons 
through the cycle both groups, consistent with the relative number of steps from acetyl-
CoA entry into the cycle.  Also, rotenone induced increased incorporation of [1,2-13C2]-
acetate into acetyl-CoA (Figure 5.3A) and decreased incorporation of labeled [13C3
15N1]-
pantothenate into CoASH and all of the measured acyl-CoA species at both 3 h and 15 h 
(Figure 5.3B).   
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Figure 5.2 Rotenone mediated effects on isotopic labeling of [U-13C6] glucose.  (A) 
Effect of rotenone on the biosynthesis of glucose-derived acetyl-CoA and succinyl-CoA.  
SH-SY5Y cells were incubated in media containing [U-13C6]-glucose and 100 nM 
rotenone or DMSO (vehicle) for 6 h.  Isotopomer distributions are shown in relation to 
the Krebs cycle.  Error bars are SEMs for n=5, * p< 0.005 compared with DMSO vehicle. 
(B) Effect of rotenone on the biosynthesis of glucose-derived citrate, aKG, succinate, and 
malate.  SH-SY5Y cells were incubated in media containing [U-13C6] glucose and 100 
nM rotenone or DMSO (vehicle) for 6 h.  Error bars are SEMs for n=4, * p< 0.005 
compared with DMSO.  
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Figure 5.3 Rotenone mediated effects on isotopic labeling of [U-13C2] acetate and [U-
13C3
15N1]-pantothenate.  (A) SH-SY5Y cells were incubated in media containing 10 mM 
[1,2-13C2]-acetate and 100 nM rotenone or DMSO (vehicle) for 6 h.  Error bars are SEMs 
for n=4, * =  p< 0.005 compared with DMSO vehicle.  (B) SH-SY5Y cells were 
incubated in media containing 3 mg/L [U-13C3
15N1]-pantothenate and 100 nM rotenone or 
DMSO (vehicle) for 3 h or 15 h.  Error bars are SEMs for n=3.  
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5.5 Discussion 
In this chapter, we have shown for the first time that rotenone not only inhibits 
glucose-derived formation of both acetyl-CoA and succinyl-CoA, it also induces an 
increase in the formation of BHB-CoA in a number of human cell lines.  The decrease in 
acetyl-CoA labeling would in fact be predicted from the decreased pyruvate 
dehydrogenase activity that occurs when there is a high NADH/NAD+ ratio,164 and is 
consistent with a recent finding that rotenone causes increased shunting of glycolytic 
intermediates into lactate.160 The absence of a decrease in the absolute concentration of 
acetyl-CoA indicates either an alternate source of acetyl-CoA or an inhibit on of acetyl-
CoA utilization.  The increased labeled acetate incorporation into acetyl-CoA (Figure 
5.3A) may also be an attempt by the rotenone treated cells to compensate for the 
decreased glucose derived acetyl-CoA. 
The decrease in succinyl-CoA levels is consistent with a recent study in 
Arabidopsis cells, in which a rapid 50% decrease in aKG, the precursor of succinyl-CoA, 
was observed after 1 h of rotenone treatment.161  This may be, in part, due an inhibition of 
aconitase, which is known to be inhibited by rotenone and ROS formation.165, 166  The 
dramatic decrease in intracellular succinyl-CoA (Figure 5.1A) would cause decreased 
protein succinylation, a post-translational modification with important regulatory 
implications.  For example, 3-hydroxy-3-methyl-glutaryl (HMG)-CoA synthase, the rate-
determining enzyme in ketogenesis is inactivated by succinylation, which is, n turn, 
regulated by succinyl-CoA concentrations.38 In addition, a recent study has shown that 
succinylation of lysine residues occurs as a post-translational regulatory modification to 
certain enzymes such as isocitrate dehydrogenase (Figure 5.2).167  In addition to 
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decreased succinyl-CoA biosynthesis, increased conversion of succinyl-CoA to succinate 
may also contribute to decreased succinyl-CoA levels.  The increased succinate could 
then be used as a complex II substrate.  Since complex I and II both ultimately reduce 
ubiquinone, the increased conversion of succinyl-CoA to succinate may allow for 
increased complex II activity to compensate for complex I inhibition.  
The rotenone-mediated increase in BHB-CoA (Figure 5.1B), an intermediate in 
fatty acid β-oxidation,168 together with the minimal incorporation of [U-13C6]-glucose 
into BHB-CoA (< 5 %) is indicative of a compensatory metabolic rearrangement to 
maintain cellular bioenergetics, allowing the cell to bypass the inhibition of glucose-
derived acetyl-CoA.  This would arise through the intermediate 3-hydroxyacyl-CoA 
dehydrogenase-mediated formation of acetoacetyl-CoA169 followed by thiolase 
(ACAT1)-mediated formation of acetyl-CoA.170  
Finally, the decreased incorporation of pantothenate into CoA (Figure 5.3B) was 
also quite striking and somewhat surprising, as we expected an increase in CoA 
utilization and turnover during a state of metabolic stress.  This does raise the intriguing 
possibility that rotenone has effects on the CoA biosynthesis pathway, though this has not
been previously documented.  Whether any or all of these changes are a pathological 
result of rotenone toxicity, physiological adaptation to diminished OXPHOS function, or 
a complex I-independent effect altogether remains to be determined.  However, th  
prolonged reliance on compensatory pathways could play an important role in rotenone 
toxicity in vivo due to differences in the abilities of different tissues or cell types to up-
regulate or maintain these metabolic rearrangements. 
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5.6 Conclusions 
In summary, we have shown that SILEC-based stable isotope dilution LC-MS 
methodology coupled with isotopomer analysis of CoA thioesters can be used in vitro to 
gain insight into the mechanisms involved in the toxicity of environmental agents such as 
rotenone.  Although rotenone does not completely mimic all aspects of PD,149 it provides 
an example of an environmental chemical, which causes a systemic defect in 
mitochondrial function that leads to selective nigrostriatal neurodegeneration.171 Stable 
isotope LC-MS approaches along with mass isotopomer experiments make it possible t  
better characterize the metabolic pathways perturbed by rotenone treatment. 
Understanding the changes that rotenone induces in disparate cell types will increase our 
understanding of why rotenone affects certain cell types such as dopaminergic neurons, 
while sparing other neurons and tissues. These biomarkers might relate specifically to PD 
but could also be potentially useful for monitoring other neurodegenerative diseases 
involving mitochondrial dysfunction.  By understanding the pathways involved, we will 
be able to use evidence based prediction of particular pathways to further identify 
potential pathways for biomarker discovery in other metabolic and neurodegenerative 
diseases.23, 131, 134, 172, 173  
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Chapter 6: CoA biomarkers in platelets: application in Friedreich’s Ataxia 
6.1 Abstract  
Friedreich’s ataxia (FA), the most prevalent inherited form of ataxia, is an 
autosomal recessive mitochondrial disease, resulting from a tri-nucleotide expansion 
(GAA) in the gene for frataxin, a protein involved in iron sulfur cluster (ISC) formation.  
The lack of good FA biomarkers hampers the ability to develop and analyze effectiv  
treatments for this disease.  There is growing evidence that metabolic dysfunction plays a 
role in the FA pathogenesis.  In this study, changes in acyl-CoA species were 
characterized using SILEC methodology in a frataxin siRNA knockdown model in 
HEK293 cells.  In addition, the SILEC method was adapted to measure CoA changes in 
freshly isolated human platelets.  Both frataxin knockdown cells and platelets from FA 
patients were found to have decreased acetyl-CoA: succinyl-CoA ratio compared to 
controls.  This represents the first time platelets have been used as a platform to measure 
changes in acyl-CoA profiles in FA.  In addition to the findings in this study, using LC-
MS methodology to measure metabolic changes in platelets may lead to novel biomarkers 
of FA as well as other metabolic and neurodegenerative diseases.  
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6.2 Introduction 
Friedreich’s ataxia (FA) is an autosomal recessive disease of mitochondrial 
dysfunction and the most common inherited form of ataxia.174  FA results from a 
trinucleotide (GAA) expansion repeat in the first intron of the frataxin gene (FXN), 
reducing levels of frataxin protein.  While the exact role of frataxin is still unknown, it is 
believed to be involved in ISC formation.175-177 This expansion leads to decreased 
efficiency of ISC-containing enzymes such as those found in complex I-III of the electron 
transport chain, as well as aconitase, a critical enzyme which converts citrate to isocitrate 
in the Krebs cycle.178 Diminished frataxin expression as well as decreased complex I 
activity occurs in a number of different tissues of FA patients.179, 180  This leads to loss of 
dorsal root ganglia neurons accompanied by loss of peripheral nerve sensory fibers.180 
FA has several characteristic clinical features.  The loss of dorsal root ganglia, 
typically in early childhood or adolescence, leads to degeneration of the dorsal columns, 
which results in the characteristic ataxia and eventually loss of ambulation.  In addition, a 
large number of patients develop insulin intolerance and diabetes mellitus.174, 180, 181  In 
the later stages of FA, hypertrophic cardiomyopathy is often the cause of death.182 
Current therapeutic strategies include the use of coenzyme Q, PPARγ agonists, iron 
chelators, N-acetylcysteine, idebenone, vitamin E, and ubiquinone, though all have 
limited efficacy.174, 175, 179, 183-187  The lack of good biomarkers limits early detection and 
hampers attempts to rationally design new therapeutic interventions.188 A  a result, most 
cases are detected clinically, when significant neuronal damage has already occurred.  
The pervasive multi-organ involvement of this mitochondrial disease, with selectiv  
tissue involvement of a severe clinical nature, is similar to that seen with rotenone 
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treatment in rats,156 and like with rotenone, may involve an underlying metabolic cause.  
In fact, a proteomic study in rats with frataxin knockdown, showed large changes in 
proteins involved in energy homeostasis and alternative energy pathways.189 Consistent 
with proteomic changes seen in the animal model, we hypothesized that there could likely 
be significant metabolic changes that might be observed in both an in vitro frataxin 
knockdown model as well as in FA patients.   
LC-MS methodology represents a highly sensitive and specific platform for 
biomarker development.91  As demonstrated throughout this thesis, CoA thioesters reflect 
both short term and long term metabolic changes in physiological, toxicological and 
pathological settings.  Unlike organic acids and acyl-carnitines, which can be found in 
higher abundance in plasma and urine, CoA species are largely intracellular and as such, 
require extracts from tissues or cells to be used as biomarkers of disease.  Sinc  the 
primary pathology of FA is in cardiomyocytes and dorsal column neurons,180 which are 
located in clinically inaccessible tissues, a surrogate tissue is required for CoA 
measurements.  Surrogate tissues are tissues from an individual that may reflect th  
disease state, though may not exhibit a pathological phenotype.  These can include buccal 
cells, dermal fibroblasts or blood cells such as red blood cells (RBCs), lymphocytes r 
platelets.  As far as blood cells, RBCs have no mitochondria, and as such do not contain a 
significant amount of CoA thioesters and therefore would not reflect a mitochondrial 
pathology.  Lymphocytes and platelets represent extractable tissues containing 
mitochondria that can be used not only to measure baseline metabolic differences for 
screening, but can also be isolated and subjected to both ex vivo challenges to toxins or 
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isotopic tracer MS analysis to further reveal underlying metabolic and mitochondrial 
disease.   
Since frataxin levels are lower in blood cells including platelets,190 we 
hypothesized that platelets might exhibit baseline differences in their CoA profile.  In 
particular, since aconitase activity is decreased in FA,191, 192 we hypothesized that 
platelets of FA patients would exhibit altered levels in the intracellular levels of succinyl-
CoA compared to healthy individuals.  In this chapter, we studied the effects of an in 
vitro frataxin knockdown using siRNA on the intracellular levels of various short chain 
acyl-CoA species.  In addition, we looked at baseline differences among FA patients nd 
age-matched controls in freshly isolated platelets. 
 
6.3 Materials and Methods 
6.3.1 Materials 
 Reagents for LC-MS measurements of short chain acyl-CoA species are desc ibed 
in section 3.3.  8.5 mL acid citrate dextrose Vacutainer tubes (Whole Blood Tube w/ 
Anticoagulant, ACD Sol A) were purchased from BD Biosciences (REF 364606).  
Frataxin (144470) and negative control siRNAs were purchased from Ambion.   
 
6.3.2 Cell culture and knockdown experiments 
 Frataxin knockdown experiments were performed by Eric Deutsch in the lab of 
David Lynch.  HEK293 cells were maintained in minimum essential medium (Invitrogen) 
supplemented with 7.5%/2.5% FBS/HS (Foundation/GIBCO), 1% pen strep (GIBCO), 
and 200 nM L-glutamine (GIBCO) at 37C, 5% CO2.  Within 24 h, when cells had 
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reached 40-50% confluency, cells were transfected for 48 h with frataxin or scramble 
siRNA.  Knockdown success was verified by western blot using an antibody directed 
toward mature frataxin protein (Mitosciences), and was expressed as a percentage of 
frataxin in parallel control samples.  CoA analysis was performed as previously described. 
 
6.3.3 Short chain acyl- CoA measurements in platelets 
 FA patients were recruited by the Friedreich Ataxia Research Alliance (FARA) 
and were seen at the Children’s Hospital of Philadelphia as part of an ongoing, 
multicenter natural history study.  In addition, age-matched volunteers were used as 
controls.  All subjects provided written informed consent before participating in study 
procedures. Blood was collected in 8.5 mL glass acid citrate dextrose Vacutainer tubes 
and transferred into 15 mL centrifuge tubes. Cells were spun at 129g for 15 min with no 
brakes. The upper platelet rich plasma (PRP) layer was transferred to a fresh tub  and 
spun at 341g for 15 min to pellet platelets.  Platelets were resuspended and sonicated in 1 
mL of 10% TCA and frozen down and stored at -80°C.  Prior to SPE purification and 
LC-MS analysis, samples were thawed and spiked with 0.2 mL acid extracted SILEC
standards.  SPE extraction of short chain acyl-CoA species as well as LC-MS parameters 
used in analysis are described in Chapter 3.6.  The analysis was performed in two 
different sets.  The first set included 4 FA patients, and 4 healthy controls, while the 
second study included 8 FA patients and 4 healthy controls.  The data from the two 
studies were combined for meta-analysis.  A schematic of the protocol used in platelets is 
diagrammed in figure 6.1. 
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Figure 6.1 Schematic for platelet CoA analysis.  PRP: platelet-rich plasma.  ISTD: 
internal standard.  
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6.4 Results 
6.4.1 siRNA knockdown of frataxinφ 
 HEK293 cells were transfected with either frataxin siRNA or scramble siRNA 
(negative control).  Western blot analysis of frataxin protein was used to assess
knockdown efficiency.  Frataxin was knocked down greater than 80% in FA patients as 
compared to controls after 48 hours (Figure 6.2). 
 
6.4.2 siRNA knckdown results in changes to short chain acyl-CoA profile 
 Transfected HEK293 cells (48 h) were processed for short chain acyl-CoA as 
previously described except in 6-well plates instead of 10 cm dishes.  As such, only t e 
more abundant CoA species (acetyl-CoA, succinyl-CoA, CoASH) were readily detected 
and analyzed.  There was a significant change in the absolute quantity of acetyl-CoA and 
succinyl-CoA in the frataxin knockdown cells as compared to the scramble control cells.  
In particular, when the ratio of acetyl-CoA to succinyl-CoA was assessed, there was a 
significant decrease in the ratio of acetyl-CoA: succinyl-CoA, contrasting what we 
observed with rotenone treatment in cell lines.  
 
6.4.3 CoA measurements in freshly isolated human platelets 
 The SILEC method developed throughout this report was adapted for CoA 
measurements in platelets.  In most ex vivo platelet studies, platelets are generally 
purified from whole blood followed by washing and resuspension in a standardized 
buffer such as Tyrode’s solution.  However, we were interested in baseline levels of these  
                                                
φ This work was performed by Eric Deutsch in the lab of David Lynch. 
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Figure 6.2 Frataxin siRNA knockdown.  HEK293 cells were transfected with either
scrambled siRNA (negative control), or frataxin siRNA for 48 hours.  (A) Western blot 
analysis of frataxin protein siRNA treated cells.  (B) Intracellular levels of acetyl-
CoA:succinyl-CoA in control and fxn knockdown cells. Each group was performed in 
triplicate. Error bars are SEMs * p < 0.05.  
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CoA species since we suspected that persistent metabolic stress among FA patients may 
be reflected in surrogate tissues such as platelets, which are known to have decrease  
complex I activity.  Due to the dynamic nature of metabolites, platelet processing times 
were reduced as much as possible.  To accomplish this, we removed the wash and 
resuspension steps and simply purified platelets with a two-step centrifugation process, 
followed by sonication in 10% TCA in the presence of SILEC internal standards.  This 
reduced the amount of time and exogenous stimuli that would affect platelets and deviate 
from baseline differences.  In lieu of normalizing CoA levels to blood volume or platelet 
counts, which can introduce additional error or increase processing time, we decidd to 
determine absolute counts of the various CoA species and express them as molar ratios to 
one another, i.e. acetyl-CoA: succinyl-CoA ratio.  The advantage of this approach is that 
it controls for differences in both volume of blood draw and platelet concentration which 
we found can vary as much as three-fold from one subject to another.  In addition to 
platelets, Ficoll-extracted lymphocytes and brushed buccal cells from the cheek were 
analyzed.  Both lymphocytes and buccal cells were found to have inadequate CoA 
material, (data not shown), likely due to lower mitochondrial content.  Platelets were 
divided into equal fractions and processed.  They were found to have adequate precision 
for all measured species with RSD < 15% when normalized with SILEC internal 
standards.  
 
6.4.3 Friedreich’s ataxia patients have decreased acetyl-CoA:succinyl-CoA 
 The method developed for platelets was applied to FA patients and age-matched 
controls.  FA patients were found to have increased levels of succinyl-CoA in their 
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platelets.  In fact, when these were normalized to acetyl-CoA levels, there was a 
significant decrease in the ratio of acetyl-CoA:succinyl-CoA (Figure 6.3).  Other short 
chain acyl-CoA species were measured, though none appeared to have a significant 
correlation with FA.  This decrease in acetyl-CoA:succinyl-CoA ratio is consistent with 
changes seen in frataxin knockdown model in vitro, though opposite to the changes seen 
with rotenone treatment, in which succinyl-CoA levels decreased relative to DMSO 
controls.   
 
6.5 Discussion 
In this study, we have demonstrated the application of platelets as a platform to 
measure baseline acyl-CoA concentrations using stable isotope dilution mass 
spectrometry.  This method was applied to FA, a mitochondrial disease involving 
metabolic dysfunction.  FA patients exhibited significant baseline differences i  major 
short chain acyl-CoA thioester species, consistent with changes exhibited in frataxin 
knockdown in vitro, namely a decrease in the molar ratio of intracellular acetyl-CoA to 
succinyl-CoA, driven largely by increases in succinyl-CoA.  Although we also 
anticipated that platelets from FA patients would exhibit similar changes to what we had 
seen with rotenone treatment in cells, the effect we found was actually the opposite of 
what we expected.  That is, rather than a decrease in succinyl-CoA, FA subject  exhibited 
an increase in succinyl-CoA.  Though the underlying cause is not clear, it may signif
compensatory changes made by the cells to overcome a metabolic deficiency.189  This 
could arise from increased anaplerotic flux from odd chained fatty acids or glutamate.193 
On the other hand, this could be a result of Krebs cycle stalling, resulting in an inhibitio   
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Figure 6.3 Acetyl-CoA: succinyl-CoA ratio in platelets in FA subjects vs. controls. Short 
chain acyl-CoA species form 12 FA subjects and 8 healthy controls were analyzed using 
the previously described methods.  
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and decreased consumption of succinyl-CoA.  If this is the case, appropriate ex vivo 
challenges such as galactose treatment rather than glucose may lead to faster or slower 
metabolic decompensation to reveal an underlying mitochondrial dysfunctional state.194 
Interestingly, although it has been shown that platelets of FA patients have decreased 
complex I expression and activity, FA patients do not exhibit significant disease at 
baseline in their blood cells.190  Moreover, FA patients not generally have any clinically 
significant deficiencies in hemostasis or platelet function, and yet still di played 
differences in platelet metabolites.  This further strengthens the hypothesis that the global 
metabolic changes in FA are occurring in all tissues, however, certain tissues are more or 
less susceptible to the pathophysiological complications of these changes.189 
There are several improvements are being considered for this approach.  Although 
significant differences were observed, subjects also showed considerable variability, 
which may have arisen in various ways.  One source is diurnal metabolic variability.  
Also, levels of various metabolites may widely vary in the blood or urine from the same 
patient after meals or after a long fast.  One potential method of controlling f r this 
variability is by drawing the blood and taking urine samples in the morning, simulating a 
fasted state, or after a standardized glucose challenge, representing a fed state.  Otherwise, 
to bring out the phenotype, an appropriate challenge may be necessary, such as placing 
platelets in Tyrode’s containing only galactose to make them more reliant on OXPH S-
derived ATP.194 Then, mitochondrial or OXPHOS dysfunction may be revealed through 
changes in metabolic or viability parameters.  In summary, we have shown t at in vitro 
models of mitochondrial dysfunction result in metabolic changes that can be detecte  in 
surrogate tissues of diseased individuals with the same genetic defect.   Further studies 
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with ex vivo metabolic challenges may further uncover FA phenotypes and lead to 
functional diagnostic tests for FA, which currently has no clinically practicl validated 
biomarkers.195 Furthermore, a well-characterized mitochondrial genetic disease such as 
FA represents an extremely valuable model to characterize the metabolic pathogenesis of 
mitochondrial dysfunction and the identification of characteristic biomarkers induced by 
this dysfunction.  
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Chapter 7:  Development of an ex vivo metabolic challenge model in platelets to 
characterize mitochondrial and metabolic physiology 
7.1 Abstract 
In this chapter, an ex vivo metabolic challenge model is developed in freshly 
isolated human platelets.   To achieve this, platelets were isolated and purified from 
whole blood and treated with propionate, rotenone or stable isotope metabolic tracers 
([U-13C6]-glucose, [6-
13C1]-glucose [1-
13C1]-propionate, [1,2-
13C2]-acetate, and 
[13C3
15N1]-pantothenate).  Subsequently, short chain acyl-CoA species were extracted 
and analyzed using SILEC standards to determine changes in absolute CoA 
concentrations, or isotopomer distribution analysis was performed to determine relative 
flux with metabolic tracers.  Platelets treated with 10 mM propionate were found to have 
a greater than 100-fold increase in propionyl-CoA after 1 h.  Also, 1 µM rotenone 
treatment in platelets resulted in a greater than 90% decrease in succinyl-CoA and a 10 
fold increase in BHB-CoA concentration.  Both propionate and rotenone-mediated 
changes were consistent with previous in vitro experiments performed on human cell 
lines.  In addition, isotopic tracers were readily incorporated and detected in en ogenous 
platelet CoA thioesters after only one hour of incubation.  Remarkably, [1,2-13C2]-acetate 
labeled more than 70% of acetyl-CoA, HMG-CoA, and BHB-CoA, as well as 30% of 
succinyl-CoA, when spiked directly into whole blood or after platelet isolation.  
Therefore, platelets were found to be a viable, metabolically active, ex vivo challenge 
model that can be adapted for diagnostic toxicological and metabolic functional tests.  
This methodology can be further used to uncover phenotypic differences in mitochondrial 
and metabolic diseases. 
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7.2 Introduction 
 There has been tremendous difficulty in developing and validating biomarkers of 
disease.196 Biomarker candidates often show promise pre-clinically, but often have poor 
performance in predicting disease during later stages of clinical developm nt or when 
used for larger studies.197 The two most critical criteria in the success of biomarkers are 
sensitivity and specificity, with both ideally being greater than 90%.198 Although many 
candidate biomarkers have adequate sensitivity, lack of specificity for many of these 
biomarkers leads to false positives, which decreases the clinical utility of these tests.  For 
metabolomic biomarkers, in particular, the dynamic nature of metabolite levels adds 
another level of complexity.199  Unlike proteins, which are often stable for hours or days, 
endogenous metabolites can turn over in seconds and can also exhibit diurnal 
variability.200 In addition, if not properly handled, concentrations of these metabolites can 
be drastically affected by improper or inconsistent sample collection and processing, due 
to their dynamic nature.  Like urinary and serum metabolites, tissue and cell metabolites 
such as CoA thioesters can also be affected by these same factors.  Moreover, since the 
measurements are done from cells, which are active biological systems themselves, 
quenching of cellular and enzymatic activity is also critical during the assay.  It is 
possible that the variability observed in the FA study (chapter 6) may be partly attributed 
to some of the biological these effects (diurnal variability, sample handling, iet, etc.).   
There are various strategies used to overcome or normalize for this variability.  
One method is using a functional test rather than a traditional biomarker.201 Traditional 
biomarkers may include a metabolite or protein that is persistently elevated or r duced in 
a particular disease state.  In a functional test, however, a specific challenge is given, 
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either in vivo or ex vivo, to uncover phenotypic differences between healthy and diseased 
individuals that may not be readily discernible when using baseline measurements.  One 
example of a functional test is a fasting blood glucose test in which glucose 
measurements are given after overnight fasting, thereby reducing the impact of recent 
food intake.  The level of circulating glucose represents a subject’s ability to 
appropriately regulate insulin and store glucose, and is elevated in diabetes mellitu  
(Types I and II) as well as certain cancers.  A oral glucose tolerance test can also be used, 
in which the subject is given an oral glucose load followed by sequential blood glucose 
measurements.202  Both fasting and oral glucose tests highlight the use of an exogenous 
challenge to reveal an underlying pathological phenotype, in this case, the inability to 
properly regulate glucose levels.  Most importantly, these types of tests establish an 
experimental baseline so that all subjects have approximately similar initi l conditions.  
Although HbA1C, a sugar-modified circulating hemoglobin, is a more preferable and 
predictive biomarker of diabetes progression largely due to its longer half-life in the 
blood, this type of biomarker is more common in proteomics than in metabolomics due to 
the longer half-life and stability of proteins in biological systems. 203  
Although both glucose tests are in vivo challenges, this approach can be 
performed ex vivo as well.  In an ex vivo test, a small samples of cells or tissues are 
extracted and isolated from the subject.  These are then challenged with a specified 
stimulus in hopes of uncovering a particular phenotype.204 The disadvantage of this 
method is that a subset of cells is being studies in isolation rather than looking at the 
system wide physiological effects as is done in a glucose load test.  The advantage, 
however, is that a much larger variety of tests can be used, including pharmacological or 
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toxicological tests that would be unsafe or unethical to perform in vivo, such as rotenone 
treatment.  In addition, since a smaller amount of cells are being tested, a much smaller 
amount of reagent or testing compound is required for the test as this does not have to 
become systemically distributed.  This is particularly useful for isotopic tracer analysis, in 
which the reagents may be prohibitively expensive and impractical to perform in vivo
dosing tests. 
We hypothesized that this functional test biomarker approach could be used in 
platelets ex vivo to help diagnose mitochondrial or metabolic diseases such as FA.  To 
achieve this, three methodological approaches are pursued in this chapter.  First, freshly 
isolated platelets were washed and treated with propionate to verify whether plaelets 
could be used as a metabolically viable ex vivo surrogate tissue.  Second, isolated 
platelets were subjected to dose-dependent rotenone treatment to determine if the 
metabolic activity seen in the cells lines (Chapter 5) can be recapitulated in an ex vivo 
toxicological model.  Finally, isolated platelets were treated with various isotopic tracer 
molecules to determine whether metabolic flux could be assessed in this model.  A 
schematic of the experimental protocol is provided in figure 7.1. 
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Figure 7.1 Scheme for isotopic tracer analysis and ex vivo platelet “challenges.”  
 
 
 
 
7.3 Methods 
7.3.1 Materials 
[6-13C1]-glucose was purchased from Cambridge Isotopes (Andover, MA).  All 
other materials used in this chapter were obtained as previously reported.   
 
7.3.2  Isolation and preparation of human platelets 
 Platelet extraction was performed similarly to what was presented in Chapter 6, 
with some modifications.  Briefly, whole blood was drawn into 8.5 mL ACD Vacutainer 
tubes (BD), transferred to 15 mL falcon tubes and spun for 15 min at 129g with no 
brakes.  The upper PRP layer was transferred to a fresh tube and spun again at 341g for 
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20 min with no brakes.  This pellet was resuspended in 5 mL HEN wash buffer (150 mM 
NaCl, 1 mM Na2EDTA, 10 mM HEPES, pH 6.5)  and was spun again at 329g with no 
brakes for 15 min.  Finally the platelet pellet was resuspended in 1 mL Tyrode’s solution 
(139 mM NaCl, 3 mM KCl, 17 mM NaHCO3, 12 mM glucose, 3 mM CaCl2, 1 mM 
MgCl2) and transferred to 1.5 mL microcentrifuge tubes.  A 10 µL aliquot was 
transferred for platelet counts which were performed on a BD platelet counter in th  
laboratory of Dr. Skip Brass. 
 
7.3.2  Ex vivo platelet “challenges”  
 Ex vivo challenges were performed on resuspended platelets in Tyrode’s solution.  
Figure 7.1 illustrates the overall experimental design.  Briefly, three different challenge 
paradigms were performed.  (1) Propionate challenge: a stock of 1mM propionate was 
prepared in water.  10 µL of this solution was added to platelets in Tyrode’s solution for a 
final concentration of 10 mM.  10 µL of water was used as control.  Incubations were 
performed in triplicate.   (2) Rotenone challenge: a 10 mM stock of rotenone was freshly 
prepared in DMSO.  Serial 10-fold dilutions were made in DMSO from 1 mM down to 
100 pM along with a 5 µM and 500 nM dilution.  Platelets from an 8.5 mL blood draw 
were resuspended in 10 mL of Tyrode’s solution and divided into equal 1 mL fractions.  
10 µL of each rotenone dilution and DMSO control were then added to each to generate a 
dosing curve from 1 pM to 100 µM in concentration.  (3) Metabolic tracer analysis.  
Stocks of five different stable isotope labeled metabolic tracers were prepared in water in 
the following concentrations: [U-13C6]-glucose (100 mg/mL), [U-
13C1]-glucose (100 
mg/mL), [1-13C1]-propionate (1M), [1,2-
13C2]-acetate (1M), and [
13C3
15N1]-pantothenate 
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(0.3 mg/mL).  10 µL of each stock was added to different tubes of resuspended platelets 
(1:100 dilution) for a final concentration of 1 mg/mL, 1 mg/mL, 10 mM, 10 mM, and 3 
mg/L, respectively.  For all three experiments, platelets were gently mixed by inversion 
and incubated in the presence of challenge at 37°C for 1 h.  After incubation, platelets 
were spun down and short chain acyl-CoA species were extracted as described in chapter 
6.  In the case of isotopic tracer analysis, no SILEC standards were used.  Finally, we lso 
evaluated the labeling of [1,2-13C2]-acetate spiked directly into whole blood (pre-spin) or 
into Tyrode’s solution after washing and purifying (post-spin).  In both cases, we used 1 
mM [1,2-13C2]-acetate.  In the case of pre-spin labeling, we harvested the platelets in the 
same fashion as was performed in Chapter 6, (without the HEN wash or Tyrode’s 
solution incubation).  This decreased the total time from blood draw to acid extraction 
down to approximately 45 min. 
 
7.4 Results 
7.4.1 Propionate challenge 
 Freshly isolated human platelets were treated with 10 mM propionate in Tyrode’s 
solution.  After 30 minutes, propionyl-CoA levels increased 10-fold and concentrations 
of acetyl-CoA and succinyl-CoA were significantly decreased (Figure 7.2).  These results 
are consistent with in vitro experiments in Hepa 1c1c7 cells (Figure 2.6), in which there 
was a similar increase in propionyl-CoA and decrease in acetyl-CoA and succinyl-CoA 
after propionate treatment observed.  Therefore, this propionate challenge demonstrated 
that platelets could be used x vivo as a metabolic functional test platform.  This can be 
further extended to include other fatty acids or nutrients as well. 
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Figure 7.2 Effect of propionate treatment on selected CoA-thioesters in isolated human 
platelets.  Platelets from one healthy subject were isolated, washed and resuspended in 
either Tyrode’s solution or Tyrode’s solution containing 10 mM propionate for 30 
minutes.  Following incubation, platelets were pelleted and processed for short chain 
acyl-CoA concentrations using SILEC methodology.  A small aliquot was taken after 
resuspension to measure platelet concentration. Each group was performed in triplicate.  
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7.4.2  Rotenone challenge 
 Platelets isolated from an 8.5 mL blood draw were divided into 10 equal fractions 
and treated with increasing doses of rotenone for 1 h, followed by short chain acyl-CoA 
thioester analysis (Figure 7.3).  Rotenone decreased intracellular succinyl-CoA levels and 
increased BHB-CoA levels in a dose-dependent manner, both with a IC50 of < 100 nM, 
consistent with the effect observed in various cell lines.  Moreover, the ratio of BHB-
CoA: succinyl-CoA was plotted as a function of rotenone dose, demonstrating a likely 
relationship between these processes (Figure 7.3).  These data show that platelets c n be 
used as ex vivo toxicological model, and can potentially be used to evaluate the effect of 
mitochondrial toxins in different disease states. 
    
7.4.3  Isotopic tracer challenge 
 Platelets were isolated from three different subjects and treated with metabolic 
tracers for 1 h, followed by CoA extraction.  Natural mass isotopomer distribution was 
calculated in unlabeled platelets and subtracted using a matrix analysis from the labeled 
cells to determine the relative isotopic labeling of each isotopomer (Figure 7.4).  Both 
[13C]-glucose reagents showed minor labeling.  However, with [1,2-13C2] acetate (10 
mM), more than 60% of acetyl-CoA was labeled indicating that acetate may be  more 
sensitive metabolic tracer to evaluate metabolic flux in the Krebs cycle during shorter 
incubations.  More strikingly, the BHB-CoA gets labeled in M2 and M4, (but not M1 and 
M3) and HMG-CoA get labeled as the M2, M4 and M6 (not M1, M3 or M5), consistent 
with incorporation of 2 carbon units from acetate.  Also, succinyl-CoA is labeled in M2, 
M3 and M4 positions indicative of multiple turns of the Krebs cycle. [1-13C1]-propionate 
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Figure 7.3 Dose-dependent effect of rotenone on succinyl-CoA and BHB-CoA in isolated 
human platelets. Platelets from one healthy subject were isolated, washed and 
resuspended in either Tyrode’s solution containing an increasing concentration of 
rotenone for 30 min.  Following incubation, platelets were pelleted and processed for 
short chain acyl-CoA concentrations.  A small aliquot was taken after resuspen ion to 
measure platelet concentration.  Figures (A) and (B) demonstrate intracellular platelet 
BHB-CoA and succinyl-CoA levels, respectively.  Figure (C) demonstrate  the ratio of 
BHB-CoA to succinyl-CoA.  
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Figure 7.4  Isotopomer distribution of selected CoA thioesters 
in freshly isolated human platelets treated with various stable 
isotope metabolic tracers.  Platelets from three control subjects 
were isolated, washed and resuspended in glucose-free 
Tyrode’s solution containing either no glucose, [U-13C6]-
glucose (1 mg/mL), [U-13C1]-glucose (1 mg/mL), [1-
13C1]-
propionate (10 mM), [1,2-13C2]-acetate (10 mM), and 
[13C3
15N1]-pantothenate (3 mg/L).  Following incubation, 
isotopic distribution of selected CoA species was determined. 
Pantothenate labeling is also plotted alone (lower right).  
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 was incorporated into [1-13C1]-propionyl-CoA (M1) and was also incorporated into 
succinyl-CoA (M1), with approximately 30% of the total succinyl-CoA being labeled 
through this anaplerotic pathway.  This reagent could potentially be used as an 
anaplerotic biomarker by measuring the incorporation of this carbon into succinyl-CoA.  
Finally, [13C3
15N1]-pantothenate (1mg/L) was readily incorporated into each of the 
measured CoA species, though at different percentages, suggesting different rates of 
turnover for each CoA thioester.  The lack of significant M4 isotopomer from the control 
cells makes this an ideal labeling reagent for isotopic tracer analysis, as nearly all of the 
M4 isotopomer comes from the labeling agent.  Furthermore, the greater increase in 
[13C3
15N1]-pantothenate labeling (such as seen in HMG-CoA) is indicative of newly 
formed CoA, and suggests a higher turnover or increased synthesis of this product.  
Therefore, using [13C3
15N1]-pantothenate tracing, in addition to evaluating tracers in the 
acyl moiety, we can also evaluate the labeling of the CoA backbone.  The lack of labeling 
in CoASH with the remaining tracers confirmed that the isotopic labeling occurred in the 
acyl group. 
 Due to the rapid labeling observed with 10 mM [1,2-13C2]-acetate labeling, we 
evaluated the labeling at 1 mM, to decrease the tendency of the high acetate 
concentration sequestering the CoA pool.  We also evaluated labeling at two different 
points in the protocol.  Either (1) directly into whole blood (pre-spin) or (2) after washing 
and purification (post-spin), followed by CoA analysis.  We found that both pre-spin and 
post-spin techniques successfully labeled the cells and was relatively consistent among 
the healthy subjects (Figure 7.5).  Many of the findings observed at 10 mM were also 
seen at 1 mM.  Further decreasing the concentration of [1,2-13C2]-acetate or performing a  
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Figure 7.5  [1,2-13C2]-acetate labeling of selected CoA thioesters in freshly isolated 
human platelets.  For pre-spin labeling, whole blood from three different control subject 
was spiked with 1 mM [13C2]-acetate, and processed as illustrated in figure 7.1.  For post-
spin labeling, platelets were isolated, washed and resuspended in 1 mL glucose-free 
Tyrode’s solution containing [13C2]-acetate (1 mM) for 1 h.  Following incubation, 
isotopic distribution of selected CoA species was determined.  Unlabeled blood was used 
in both instances to determine baseline isotopomer distribution.  
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tracer dosing study should be evaluated.  Since the pre-spin application of isotopic tracers 
was successful in labeling these CoA species, a commercially available b ood collection 
tube containing the labeling reagent of interest dissolved in the buffer represents a 
powerful and clinically applicable diagnostic tool. 
 
7.5 Discussion 
 In this chapter, we have shown that freshly isolated human platelets can be used 
as an ex vivo platform for a variety of challenges or functional tests.  This type of test 
could be used to characterize metabolic physiology or uncover metabolic and 
mitochondrial pathophysiology.  First, we demonstrated that in 1 h, an exogenous fatty 
acid such as propionate can be incorporated into propionyl-CoA in platelets.  This could 
potentially be used as a diagnostic tool for a disease like propionyl-CoA carboxylase 
deficiency.205, 206 Insufficient downstream products or a buildup of propionyl-CoA may 
reveal an enzymatic deficiency. 
 Second, the rotenone challenge model revealed another potentially powerful 
application of this method.  We demonstrated that rotenone treatment in isolated platelets 
recapitulates the phenotype seen with cell lines.  This not only further strengthens our 
original findings for rotenone-mediated changes in intracellular CoA species (particularly 
succinyl-CoA and BHB-CoA), but also demonstrates that platelets are a viable surrogate 
tissue to study mitochondrial or metabolic dysfunction.  In diseases such as FA, where an 
underlying metabolic disease manifests clinically in certain tissues, this type of approach 
may be used diagnostically to uncover disease.  For instance, FA patients may exhibit 
increased sensitivity to rotenone, where a lower dose may exacerbate CoA changes due to 
118 
 
a lower toxic threshold.  Conversely, FA patients may exhibit decreased sensitivity to 
rotenone treatment due to metabolic compensation at baseline and increased reliance on 
glycolysis.  These changes must ultimately be determined empirically.  This would not 
only improve diagnostic capabilities, but also help us understand pathological 
mechanisms that occur in FA.  The destruction of a specific group of neuronal cells while 
sparing nearby cells, is also a distinctive feature of other neurodegenerative diseases such 
as PD, AD, and ALS in which nigrastriatal, cerebral cortical, and spinal motor neurons 
are degraded, respectively.  Thus, this assay may be useful for other neurodegenerative 
diseases as well. 
 Finally, and perhaps the most valuable application of this methodology is the ex
vivo isotopic tracer analysis.  We have demonstrated that in as little as one hour, five 
different isotopic tracers were incorporated and could be readily detected in the 
metabolites extracted from freshly isolated platelets.  In fact, therear  hundreds or even 
thousands of different stable isotope metabolic tracers that could likewise be used. In 
addition to the changes in absolute concentrations of these metabolites, this methodology 
allows characterization of the flux through these pathways as well.207 This would 
improve diagnostic capabilities for many metabolic diseases.  Nonetheless, th  proper 
tracer, time of application, and sample handling techniques need to be optimized for each 
disease.  For longer incubations, lymphocytes or fibroblasts could be used since platelets 
cannot be cultured overnight.204, 208 In fact, there is evidence that platelets from PD, AD 
and ALS patients as well as fibroblasts from AD patients exhibit decreased glutamate 
uptake.209-212 Using the methodology developed here, we would not only be able to more 
quantitatively analyze glutamate uptake, but by using a labeled glutamate tracer, we 
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would be able to determine the fate of the labeled glutamate.  Since glutamate can serve 
as an anaplerotic substrate, decreased glutamate uptake may manifest in decreased 
incorporation of labeled carbons into aKG and downstream metabolites.  This is just one 
of many potential applications of this assay. 
There are certain limitations to this approach over classic biomarker approaches.  
In particular, the requirement of fresh viable cells makes logistical clinical application 
challenging and also limits any study that proposes using historical or previously 
collected samples.  In addition, rigorous adherence to standardized protocols would be 
required not only for sample collection, but also for ex vivo challenge, extraction and 
analysis.  Additionally, improper or inconsistent handling could result in significant 
metabolic disturbances which could lead to erroneous conclusions. On the other hand, the 
ability to collect, wash and resuspend platelets ex vivo prior to testing affords increased 
standardization and reduces variability that may arise from previously described external 
factors.  In total, however, platelets represent not only a novel surrogate tissu  to study 
metabolism, but these approaches provide a methodological advance in biomarker 
development.  By using functional metabolic tests, much richer and more dynamic data 
sets can be generated than from classical biomarker studies.   
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Chapter 8: Conclusions and Future Directions 
8.1 Conclusions  
 In this thesis, we have developed a method to generate SILEC-labeled CoA 
standards and utilized them to rigorously measure short chain acyl-CoA thioester n cell 
culture, various animal tissues and clinical samples.  These not only improved the 
specificity of CoA measurement, but also improved accuracy and precision of the 
measurements.  By utilizing the lack of a de novo biosynthetic pathway, we were able to 
generate nearly isotopically pure CoA species biosynthetically in both mammalian and 
insect cell lines.  The extracted species were then applied to biological samples to 
measure changes in CoA molecules.  We also improved upon previously developed 
isotopic tracer analysis to monitor intracellular flux of labeled carbons through different 
pathways by performing isotopomer distribution analysis on the different CoA specie .  
Together, these methods allowed us to more confidently monitor changes in the absolute 
concentration of several important CoA species in cell culture, animal tissue and platelet 
samples as well as the turnover and flux through these species in v tro. 
 Applying these standards to biological samples led to three important findings.  
First, using a novel LC-SRM/MS method to monitor intramitochondrial oxidative stress 
by monitoring ratio of CoASSG: CoASH, it was found that these levels increased 
dramatically at high menadione doses.  Similar doses of rotenone, also known to generate 
ROS in mitochondria, did not appear to increase these levels, suggesting that CoASSG 
may be involved in the detoxification of xenobiotics and electrophiles within the 
mitochondria.  Second, it was found, that rotenone dramatically changed in the short 
chain acyl-CoA thioester profile in a number of different cell lines, including 
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neuroblastoma (SH-SY5Y), hepatoma (HepG2) and bronchioalveolar carcinoma (H358) 
cells.  In particular, rotenone induced a dose-dependent decrease in succinyl-CoA and 
increase in BHB-CoA.  Isotopic tracer analysis revealed that rotenone inhibited [U-13C6]-
glucose-derived acetyl-CoA and succinyl-CoA biosynthesis in SH-SY5Y neuroblast m  
cells.   
Finally, this SILEC method was adapted for use in freshly isolated human 
platelets.  Extracted platelets were used to characterize differences in short chain acyl-
CoA concentrations between healthy controls and patients with FA, a mitochondrial 
disease for which metabolic dysfunction is known to play a role.  A significant decrease 
in the acetyl-CoA: succinyl-CoA concentration was observed in FA patients and was 
consistent with an in vitro frataxin knockdown model.  In addition to being used as a 
surrogate source of CoA and mitochondrial metabolites, we also demonstrated that 
platelets could be used as a platform for ex vivo metabolic and toxicological challenges.  
In addition, we also demonstrated that platelets could be used to trace isotopically labeled 
metabolic nutrients through various biochemical pathways.   
 
 
8.2 Future Directions 
8.2.1  Expansion of in vitro, in vivo and ex vivo models 
Cancer cell lines were used for the majority of our work with rotenone-induced 
metabolic derangement. While cancer cell lines are both easier to work with and are more 
uniform between experiments, they are known to differ metabolically from pri ary lines. 
In particular, the Crabtree or Warburg effect, a phenomenon in which cancer cells 
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become more glycolytic and may derive as much as 95 % of their ATP from 
glycolysis.194, 213 Using rotenone to inhibit mitochondrial respiration in highly glycolytic 
cells may not induce as dramatic a phenotype as cells more reliant on mitochondria f r 
ATP.  One method of avoiding this is by replacing glucose with galactose. In the case of 
galactose, cells do not generate a net gain of ATP through glycolysis and therefore 
become more reliant on mitochondria for cellular ATP. These OXPHOS-dependent cells 
are subsequently more sensitive to mitochondrial inhibitors.194 Another way to overcome 
this problem is by using primary cell lines, which may more closely resemble the 
metabolic state of these tissues in rodents and humans. The drawback to using primary 
cells is the difficulty in isolating a particular cell type.  In the case of primary neuronal 
cells, glial cells often contaminate and complicate the analysis. Neverth less, a 
comparison to primary cells will be important in confirming the changes that are 
observed in the cell lines. Preliminary data indeed demonstrates that the rotenone-
mediated metabolic changes observed with the cell lines (Chapter 5) were recapitulated in 
primary cortical rat neurons.   
In addition, application to neuronal tissue is actively being pursued.  The rotenone 
rat model of PD has been widely used and provides a well validated system to study 
mitochondrial dysfunction in neurodegenerative disease.152 We hypothesize that chronic 
low dose treatment of rotenone in rats will lead to compensatory or pathological 
metabolic derangement that will manifest in a variety of tissues including the brain, 
though most dramatically in particular regions such as the substantia nigra.   
 
8.2.2 Measuring other organic acids and Krebs cycle intermediates 
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This thesis was primarily focused on changes in short chain acyl-CoA species. 
These were important in understanding changes in several metabolites within or proximal 
to the Krebs cycle.  While understanding changes in acyl-CoA species undoubtedly 
improves our ability to explore pathological changes in numerous metabolic pathways, it 
only gives us a partial picture.  Further studies exploring changes in organic acids such as 
those in the Krebs cycle can give us a better understanding of these changes.  In fact, we 
are currently developing an LC-MS method to measure changes in numerous organic
acids using a derivatization procedure with MTBSTFA, a derivatizing agent commonly 
used for GC-MS.163 Using this reagent, we have been able to measure changes and 
isotopic labeling in citrate, aKG, succinate, fumarate, malate, oxaloacetate and lactate.  
Measurements in pyruvate, isocitrate, acetoacetate, BHB, glutamate, and many other fatty 
acid and cellular nutrients are currently being developed.  In addition to expanding the 
number of metabolites measured, a larger panel of isotopic tracers will be developed to 
further explore the effects of rotenone, FA and other mitochondrial diseases in vitro as 
well as in platelets.   
 
8.2.3 Measuring the human “CoA-balome” 
 Throughout this thesis, we have primarily focused on measuring short chain acyl-
CoA species for a number of reasons.  Most importantly, these molecules are involved at 
the intersection of many central metabolic pathways such as glycolysis, the Krebs cycle 
and FAO.  Nonetheless, they represent only a small fraction of the many CoA-derivativ s 
including medium, long and very long chain acyl-CoA thioesters, not to mention 
numerous xenobiotic CoA adducts (appendix, Table A.1).  In addition, novel CoA 
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derivatives such as CoA-RNA adducts and CoA-hydroxynonenal adducts have recently 
been discovered, though the function and mechanism of formation of these molecules 
remains unclear. 43, 56   Together, all of these species illustrate the complexity as well as 
the rich abundance of measurable CoA species.  Much like the genome has given way to 
the transcriptome, and the proteome can be further dissected into the phospho-proteome, 
the human metabolome is also much too complex to be analyzed using a single method.  
In fact, the multitude of CoA molecules represent a “CoA-balome,” the subset of all CoA 
derivatives, that might require a systems biology approach to study.  It is possible, and 
even likely, that each mitochondrial or metabolic disease would have a unique CoA 
fingerprint either at baseline or under some experimentally induced stress.  Thi  may only 
be seen in disease-specific tissues, in which case the assays we developed may allow 
further understanding of the pathogenic mechanisms of these diseases.  On the other 
hand, these may exhibit changes in surrogate tissues as well, as growing evidenc  
suggests underlying metabolic causes for many diseases.  The ability afforded by newer 
software platforms combined with the ability to do perform CoA discovery using neutral 
loss scanning of CoA (m/z 507) would allow a tremendously powerful approach to 
diagnosing a variety of diseases.  By increasing the breadth of this assay to include a 
larger subset of CoA species, and combining it with isotopic tracer analyses, new disease 
biomarkers may be discovered for a multitude of diseases. 
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Table A.1 CoA-thioesters and derivatives, including unlabeled and SILEC labeled parent 
ion masses (m/z MH+, amu).  Previously published (Basu SS, Blair IA. Nat Protocols, 
2011). 
SILEC
Coenzyme A thioester MH+ MH+
(amu) (amu)
CoASH 768 772
Formyl-CoA 796 800
Acetyl-CoA 810 814
Acrylyl-CoA 822 826
Propionyl-CoA 824 828
Methacrylyl-CoA 836 840
Crotonoyl-CoA 836 840
Butyryl-CoA 838 842
Isobutyryl-CoA 838 842
Beta-Alanyl-CoA 839 843
3-Hydroxypropionyl-CoA 840 844
Lactyl-CoA 840 844
Tiglyl-CoA 850 854
3-Methylcrotonyl-CoA 850 854
Acetoacetyl-CoA 852 856
Isovaleryl-CoA 852 856
Pentanoyl-CoA 852 856
2-Methylbutyryl-CoA 852 856
L-3-Aminobutyryl-CoA 853 857
Malonyl-CoA 854 858
3-Hydroxybutyryl-CoA 854 858
(S)-3-Hydroxyisobutyryl-CoA 854 858
trans-2-Hexenoyl-CoA 864 868
trans-3-Hexenoyl-CoA 864 868
2-Methylacetoacetyl-CoA 866 870
Hexanoyl-CoA 866 870
Succinyl-CoA 868 872
S-Methylmalonyl-CoA 868 872
R-Methylmalonyl-CoA 868 872
Methylmalonyl-CoA 868 872
3-Hydroxyisovaleryl-CoA 868 872
2-Methyl-3-hydroxybutyryl-CoA 868 872
Benzoyl-CoA 872 876
Cyclohex-1,5-diene-1-carboxyl-CoA 874 878
Itaconyl-CoA 880 884
Glutaconyl-CoA 880 884
3-Oxohexanoyl-CoA 880 884
2-Methylhexanoyl-CoA 880 884
Heptanoyl-CoA 880 884
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Table A.1 CoA-thioesters and derivatives (cont.) 
SILEC
Coenzyme A thioester MH+ MH+
(amu) (amu)
Glutaryl-CoA 882 886
(S)-Hydroxyhexanoyl-CoA 882 886
Malyl-CoA 884 888
Salicyl CoA 886 890
Phenylacetyl-CoA 886 890
4-hydroxybenzoyl-CoA 888 892
3-trans,5-cis-Octadienoyl-CoA 888 892
6-Oxocyclohex-1-ene-1-carboxyl-CoA 890 894
2-trans,4-trans-Octadienoyl-CoA 890 894
6-Hydroxycyclohex-1-ene-1-carboxyl-CoA 892 896
(2E)-Octenoyl-CoA 892 896
S-2-Octenoyl CoA 892 896
3-Methylglutaconyl-CoA 894 898
Valproyl-CoA 894 898
Octanoyl-CoA 894 898
Adipoyl-CoA 896 900
L-Citramalyl-CoA 898 902
4-Hydroxyphenylacetyl-CoA 902 906
2,6-Dimethylheptanoyl-CoA 904 908
3-Oxooctanoyl-CoA 908 912
Nonanoyl-CoA 908 912
(S)-Hydroxyoctanoyl-CoA 910 914
(3S)-3-Hydroxyadipyl-CoA 912 916
3-Hydroxy-3-methylglutaryl-CoA 912 916
2,4-Decadienoyl-CoA 918 922
cis-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA 918 922
trans-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA 918 9 22
(2E)-Decenoyl-CoA 920 924
4-cis-Decenoyl-CoA 920 924
trans-3-Decenoyl-CoA 920 924
trans-D-Decenoyl-CoA 920 924
Decanoyl-CoA (n-C10:0CoA) 922 926
3-Oxopimelyl-CoA 924 928
3-Hydroxypimelyl-CoA 926 930
Pseudoecgonyl-CoA 935 939
3-Hydroxy-2,6-dimethyl-5-methylene-heptanoyl-CoA 93 6 940
3-Oxodecanoyl-CoA 936 940
Undecanoyl-CoA 936 940
4,8-Dimethylnonanoyl-CoA 936 940
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Table A.1 CoA-thioesters and derivatives (cont.) 
SILEC
Coenzyme A thioester MH+ MH+
(amu) (amu)
(S)-Hydroxydecanoyl-CoA 938 942
(2E)-Dodecenoyl-CoA 944 948
cis,cis-3,6-Dodecadienoyl-CoA 946 950
trans,cis-Lauro-2,6-dienoyl-CoA 946 950
Trans-2,3-dehydrododecanoyl-CoA 948 952
3Z-dodecenoyl-CoA 948 952
Lauroyl-CoA 950 954
E-Phenylitaconyl-CoA 956 960
(R)-Benzylsuccinyl-CoA 958 962
3(S)-3-hydroxydodecen-(5Z)-oyl-CoA 960 964
(3S)-3-Hydroxydodec-cis-6-enoyl-CoA 960 964
3-Oxododecanoyl-CoA 964 968
(S)-3-Hydroxydodecanoyl-CoA 966 970
(3E,5Z,8Z)-Tetradecatrienoyl-CoA 968 972
(2S,6R,10R)-Trimethyl-2E-hendecenoyl-CoA 972 976
2-Carboxymethyl-3-hydroxyphenylpropionyl-CoA 974 978
(2S,6R,10R)-Trimethyl-hendecanoyl-CoA 974 978
5-cis-8-cis-Tetradecadienoyl-CoA 974 978
(2E)-Tetradecenoyl-CoA 976 980
Tetradecanoyl-CoA 978 982
trans-2-Enoyl-OPC4-CoA 986 990
(3S)-3-Hydroxy-cis-8-tetradecenoyl-CoA 988 992
OPC4-CoA 988 992
3-Oxotetradecanoyl-CoA 992 996
(S)-3-Hydroxytetradecanoyl-CoA 994 998
(4R,8R,12R)-Trimethyl-2E-tridecenoyl-CoA 1000 1004
(2E)-Hexadecenoyl-CoA 1000 1004
Palmitoleyl CoA 1004 1008
Palmitelaidoyl-CoA 1004 1008
Palmitoyl-CoA 1006 1010
(3S)-3-Hydroxy-cis,cis-palmito-7,10-dienoyl-CoA 101 4 1018
trans-2-Enoyl-OPC6-CoA 1014 1018
(S)-3-hydroxypalmitoleoyl-CoA 1016 1020
OPC6-CoA 1016 1020
3-Oxohexadecanoyl-CoA 1020 1024
Heptadecanoyl CoA 1020 1024
(S)-3-Hydroxyhexadecanoyl-CoA 1022 1026
Stearidonoyl-CoA 1026 1030
Gamma-linolenoyl-CoA 1028 1032
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Table A.1 CoA-thioesters and derivatives (cont.) 
SILEC
Coenzyme A thioester MH+ MH+
(amu) (amu)
Alpha-Linolenoyl-CoA 1028 1032
Linoleoyl-CoA 1030 1034
trans-Octadec-2-enoyl-CoA 1032 1036
cis-Vaccenoyl CoA 1032 1036
Oleoyl-CoA 1032 1036
Stearoyl-CoA 1034 1038
(3S)-3-Hydroxylinoleoyl-CoA 1042 1046
trans-2-Enoyl-OPC8-CoA 1042 1046
OPC8-CoA 1044 1048
3-hydroxyoctadecanoyl-CoA 1046 1050
3-Oxooctadecanoyl-CoA 1046 1050
Retinoyl CoA 1050 1054
Timnodonyl CoA 1052 1056
3-Hydroxyhexdecanedioyl-CoA 1052 1056
5Z,8Z,11Z,14Z-eicosatetraenonyl-CoA 1054 1058
Arachidonyl-CoA 1054 1058
Pristanoyl-CoA 1062 1066
Eicosanoyl-CoA 1062 1066
Phytanoyl-CoA 1062 1066
Glutathione-CoA (CoASSG) 1073 1077
2,4,7,10,13,16,19-Docosaheptaenoyl-CoA 1076 1080
Clupanodonyl CoA 1076 1080
2-Hydroxyphytanoyl-CoA 1078 1082
Docosa-4,7,10,13,16-pentaenoyl CoA 1080 1084
Docosanoyl-CoA 1086 1090
8Z,11Z,14Z-eicosatrienoyl-CoA 1096 1100
Trans-2-all-cis-6,9,12,15,18,21-tetracosaheptaenoyl -CoA 1100 1104
Tetracosahexaenoyl CoA 1106 1110
Tetracosatetraenoyl CoA 1110 1114
(3S)-Hydroxy-tetracosa-6,9,12,15,18,21-all-cis-hexa enoyl-CoA 1118 1122
Tetracosanoyl-CoA 1118 1122
Chenodeoxyglycocholoyl-CoA 1142 1146
Chenodeoxycholoyl-CoA 1142 1146
Hexacosanoyl-CoA 1142 1146
Choloyl-CoA 1158 1162
3a,7a-Dihydroxy-5b-cholest-24-enoyl-CoA 1182 1186
3a,7a-Dihydroxy-5b-24-oxocholestanoyl-CoA 1198 1202
3a,7a,12a-Trihydroxy-5b-cholest-24-enoyl-CoA 1198 120 2
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Table A.2 Amounts of intracellular CoA thioesters formed (pmol/plate) on days after 
splitting mouse Hepa cells. Previosuly published in Basu et al. Anal Chem, 2011, 
Supporting Information. 
 
 
 
 
 
 
Table A.3 Correlation coefficients for linearity of standard curves for various CoA 
species using SILEC standards (bold) compared with structural analog i ternal standards 
(normal). Previosuly published in Basu et al. Anal Chem, 2011, Supporting Information. 
Day Acetyl-CoA Succinyl-CoA CoASH HMG-CoA Propionyl-CoA
1 5.3 18.3 1.0 0.3 0.2
2 13.0 29.9 2.4 0.5 0.4
3 32.3 80.9 19.1 2.3 1.0
4 110.0 152.9 47.3 8.0 3.7
5 91.9 213.1 91.9 4.0 6.0
6 78.3 108.0 75.8 0.9 2.0
7 68.0 84.5 118.0 0.8 1.9
CoASH Succinyl-CoA HMG-CoA Acetyl-CoA Propionyl-CoA
CoASH 0.9966 0.9922 0.9877 0.9948 0.9922
Succinyl-CoA 0.9652 0.9996 0.9937 0.9982 0.9991
HMG-CoA 0.9688 0.9996 0.9939 0.9993 0.9983
Acetyl-CoA 0.8443 0.9978 0.8098 0.9990 0.9958
Propionyl-CoA 0.9585 0.9992 0.9975 0.9983 0.9999
C
oA
Stable Isotope Internal Standard
C
oA
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Table A.4. Absolute levels of CoASH and several short chain acyl-CoA thioesters in SH-
SY5Y cells treated with rotenone measured using SILEC methodology.  Concentrations 
are presented as pmol/106 cells +/- SEM (triplicate).  When compared to DMSO controls, 
p < 0.05 (italics) and p < 0.005 (bold). Published in Basu, Blair. Chem Res Toxicol, 2011. 
 
Acetyl-CoA Succinyl-CoA CoASH BHB-CoA Propionyl-CoA HMG-CoA
DMSO 8.68 + 0.70 3.37 + 0.10 2.42 + 0.17 0.065 + 0.002 0.047 + 0.003 0.59 + 0.01
10pM 7.05 + 0.33 2.88 + 0.30 3.12 + 1.28 0.065 + 0.002 0.036 + 0.006 0.64 + 0.02
100pM 8.99 + 0.33 2.98 + 0.07 2.97 + 0.87 0.070 + 0.001 0.042 + 0.006 0.62 + 0.07
1nM 9.53 + 0.51 2.48 + 0.10 3.52 + 0.21 0.079 + 0.008 0.049 + 0.002 0.83 + 0.12
10nM 8.21 + 0.18 2.23 + 0.09 2.13 + 0.32 0.086 + 0.002 0.041 + 0.002 0.73 + 0.06
100nM 9.54 + 0.74 0.99 + 0.02 1.93 + 0.30 0.177 + 0.008 0.019 + 0.003 1.05 + 0.16
1uM 10.25 + 0.21 0.66 + 0.04 2.19 + 0.57 0.241 + 0.027 0.010 + 0.003 1.05 + 0.21
DMSO 11.46 + 0.44 9.52 + 0.81 10.76 + 1.50 0.170 + 0.008 0.704 + 0.029 2.02 + 0.21
10pM 8.78 + 0.72 6.78 + 0.35 6.73 + 0.43 0.150 + 0.003 0.601 + 0.037 1.60 + 0.04
100pM 11.49 + 0.62 7.71 + 0.45 8.77 + 1.07 0.164 + 0.002 0.740 + 0.049 1.76 + 0.10
1nM 9.35 + 0.85 7.21 + 0.69 6.09 + 0.67 0.163 + 0.019 0.586 + 0.035 1.84 + 0.20
10nM 10.13 + 0.93 7.25 + 0.13 6.78 + 0.35 0.170 + 0.011 0.783 + 0.035 2.29 + 0.08
100nM 10.51 + 0.15 4.39 + 0.23 5.36 + 0.41 0.325 + 0.012 0.735 + 0.018 2.00 + 0.08
1uM 12.05 + 0.46 2.08 + 0.06 5.42 + 1.17 0.582 + 0.003 0.719 + 0.059 2.10 + 0.16
DMSO 14.76 + 0.82 7.48 + 0.60 5.82 + 1.12 0.158 + 0.006 0.157 + 0.005 2.08 + 0.19
10pM 12.32 + 0.29 7.36 + 0.20 4.86 + 0.41 0.160 + 0.015 0.157 + 0.011 1.85 + 0.04
100pM 12.20 + 0.43 7.83 + 0.40 4.44 + 0.08 0.152 + 0.006 0.146 + 0.001 1.83 + 0.23
1nM 10.94 + 0.91 7.02 + 0.12 5.13 + 0.69 0.212 + 0.010 0.179 + 0.018 1.62 + 0.07
10nM 11.44 + 0.16 6.28 + 0.20 5.19 + 0.42 0.358 + 0.002 0.222 + 0.011 1.91 + 0.19
100nM 9.05 + 0.65 2.39 + 0.13 3.45 + 0.19 0.713 + 0.006 0.174 + 0.005 1.17 + 0.11
1uM 10.44 + 0.34 1.30 + 0.14 3.87 + 0.57 1.103 + 0.101 0.150 + 0.015 1.36 + 0.07
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Figure A.1 LC-SRM/MS chromatogram of acid extracted SILEC-labeled short chain 
acyl-CoA internal standards demonstrating isotopic purity. Previosuly published in Basu 
et al. Anal Chem, 2011, Supporting Information. 
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Figure A.2 LC-MS (SRM) chromatograms of (A) malonyl-CoA and BHB-CoA standards 
(1 pmol each) and (B) acid extracted and SPE CoA species from Hepa 1c1c7 cells.  
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